Skip to Main content
Number of documents

384

François Bertucci


Journal articles378 documents

  • Pascaline Boudou‐rouquette, Elodie Martin, Emmanuelle Kempf, Nicolas Penel, Maud Toulmonde, et al.. Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group. International Journal of Cancer, Wiley, 2022, 150 (5), pp.825-836. ⟨10.1002/ijc.33837⟩. ⟨hal-03560233⟩
  • Violette Azzoni, Julien Wicinski, Manon Macario, Martin Castagné, Pascal Finetti, et al.. BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells. Cell Death and Disease, Nature Publishing Group, 2022, 13 (2), pp.96. ⟨10.1038/s41419-022-04538-w⟩. ⟨hal-03623505⟩
  • yi Xiao, Ding Ma, yun-Song yang, Fan yang, Jia-Han Ding, et al.. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Research, Nature Publishing Group, 2022, ⟨10.1038/s41422-022-00614-0⟩. ⟨hal-03623509⟩
  • C. Moreau-Bachelard, L. Campion, M. Toulmonde, A. Le Cesne, M. Brahmi, et al.. Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG). ESMO Open, European Society for Medical Oncology, 2022, 7 (2), pp.100402. ⟨10.1016/j.esmoop.2022.100402⟩. ⟨hal-03623511⟩
  • Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, et al.. Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. Molecular Oncology, Elsevier, In press, ⟨10.1002/1878-0261.13188⟩. ⟨hal-03606435⟩
  • Chaïma Cherif, Dang Tan Nguyen, Clément Paris, Thi Khanh Le, Thibaud Sefiane, et al.. Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene, Nature Publishing Group, 2022, 41 (1), pp.125-137. ⟨10.1038/s41388-021-02039-2⟩. ⟨hal-03599176⟩
  • Justine Gantzer, Guillaume Davidson, Bujamin Vokshi, Noëlle Weingertner, Antoine Bougoüin, et al.. Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors. Oncologist, AlphaMed Press, 2022, ⟨10.1093/oncolo/oyac040⟩. ⟨hal-03623495⟩
  • Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, et al.. Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. Molecular Oncology, Elsevier, 2022, ⟨10.1002/1878-0261.13188⟩. ⟨hal-03583253⟩
  • Francois Bertucci, Vincent Niziers, Alexandre de Nonneville, Pascal Finetti, Léna Mescam, et al.. Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. Journal for Immunotherapy of Cancer, BMJ Publishing Group 2022, 10 (1), pp.e003687. ⟨10.1136/jitc-2021-003687⟩. ⟨hal-03583256⟩
  • Alexandre de Nonneville, Pascal Finetti, Emilie Mamessier, François Bertucci. RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. JNCI: Journal of the National Cancer Institute, Oxford University Press (OUP), 2022, ⟨10.1093/jnci/djac031⟩. ⟨hal-03583244⟩
  • Alexia Lopresti, Claire Acquaviva, Laurys Boudin, Pascal Finetti, Séverine Garnier, et al.. Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients. Cancers, MDPI, 2022, 14 (4), pp.932. ⟨10.3390/cancers14040932⟩. ⟨hal-03637735⟩
  • Alexia Lopresti, Claire Acquaviva, Laurys Boudin, Pascal Finetti, Séverine Garnier, et al.. Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients. Cancers, MDPI, 2022, 14 (4), pp.932. ⟨10.3390/cancers14040932⟩. ⟨hal-03583233⟩
  • Alexandre de Nonneville, F. Bertucci, Éric Lambaudie, Gilles Houvenaeghel, Renaud Sabatier, et al.. Évolution et facteurs associés à la publication des travaux de thèse d’exercice par les internes d’oncologie médicale en France. Bulletin du Cancer, John Libbey Eurotext, 2022, ⟨10.1016/j.bulcan.2022.01.009⟩. ⟨hal-03623519⟩
  • Charlotte Rypens, F. Bertucci, Pascal Finetti, Fredika Robertson, Sandra Fernandez, et al.. Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. npj Breast Cancer, Nature, 2022, 8 (1), pp.12. ⟨10.1038/s41523-021-00379-6⟩. ⟨hal-03623626⟩
  • Victoire Gouirand, Tristan Gicquel, Evan Lien, Emilie Jaune‐pons, Quentin da Costa, et al.. Ketogenic HMG‐CoA lyase and its product β‐hydroxybutyrate promote pancreatic cancer progression. EMBO Journal, EMBO Press, 2022, ⟨10.15252/embj.2021110466⟩. ⟨hal-03623502⟩
  • yue Gong, Peng Ji, yun-Song yang, Shao Xie, Tian-Jian yu, et al.. Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. Cell Metabolism, Elsevier, 2021, 33 (1), pp.51-64.e9. ⟨10.1016/j.cmet.2020.10.012⟩. ⟨hal-03623115⟩
  • Jean-Emmanuel Kurtz, Xavier Buy, Frédéric Deschamps, Erik Sauleau, Amine Bouhamama, et al.. CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. European Journal of Cancer, Elsevier, 2021, 143, pp.78-87. ⟨10.1016/j.ejca.2020.10.035⟩. ⟨hal-03623642⟩
  • Christophe van Berckelaer, Iris Vermeiren, Leonie Vercauteren, Charlotte Rypens, Gizem Oner, et al.. The Evolution and Prognostic Role of Tumour-Infiltrating Lymphocytes and Peripheral Blood-Based Biomarkers in Inflammatory Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Cancers, MDPI, 2021, 13 (18), pp.4656. ⟨10.3390/cancers13184656⟩. ⟨hal-03623094⟩
  • Almudena Callejo, Sara Faouzi, Olivier Bouché, F. Bertucci, Thomas Chevalier, et al.. Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study. Targeted Oncology, Springer Verlag (Germany), 2021, 16 (4), pp.485-492. ⟨10.1007/s11523-021-00820-7⟩. ⟨hal-03623633⟩
  • Alexandre Nonneville, Pascal Finetti, Daniel Birnbaum, Emilie Mamessier, François Bertucci. WEE1 Dependency and Pejorative Prognostic Value in Triple‐Negative Breast Cancer. Advanced Science, Wiley Open Access, 2021, 8 (17), pp.2101030. ⟨10.1002/advs.202101030⟩. ⟨hal-03583269⟩
  • Dang Tan Nguyen, Thi Khanh Le, Clément Paris, Chaïma Cherif, Stéphane Audebert, et al.. Antisense Oligonucleotide-Based Therapeutic against Menin for Triple-Negative Breast Cancer Treatment. Biomedicines, MDPI, 2021, 9 (7), pp.795. ⟨10.3390/biomedicines9070795⟩. ⟨hal-03599175⟩
  • Roxane Mari, Christophe Pomel, Pierre-Emmanuel Colombo, Fabrice Narducci, Séverine Garnier, et al.. Circulating tumor DNA as a noninvasive marker of resectability in ovarian carcinomas.. Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (15_suppl), pp.5548-5548. ⟨10.1200/JCO.2021.39.15_suppl.5548⟩. ⟨hal-03622754⟩
  • Jean-Luc Raoul, Marie-Françoise Heymann, Frédéric Dumont, Alain Morel, Hélène Senellart, et al.. Case Report: Grade 2 Metastatic Pancreatic Neuroendocrine Tumor With Progression of One Metastasis After Pregnancy to Grade 3 Large-Cell Neuroendocrine Carcinoma: One Case Cured by Resection With Genomic Characterization of the Two Components. Frontiers in Oncology, Frontiers, 2021, 11, ⟨10.3389/fonc.2021.646992⟩. ⟨hal-03623095⟩
  • D. Dano, A. Lardy-Cleaud, A. Monneur, N. Quenel-Tueux, C. Levy, et al.. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). ESMO Open, European Society for Medical Oncology, 2021, 6 (4), pp.100220. ⟨10.1016/j.esmoop.2021.100220⟩. ⟨hal-03426433⟩
  • François Bertucci, Anthony Gonçalves, Arnaud Guille, José Adelaïde, Séverine Garnier, et al.. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Medicine, BioMed Central, 2021, 13 (1), pp.87. ⟨10.1186/s13073-021-00897-9⟩. ⟨hal-03583277⟩
  • Cecile Vicier, Patrick Sfumato, Nicolas Isambert, Florence Dalenc, Marie Robert, et al.. TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. European Journal of Cancer, Elsevier, 2021, 159, pp.205-214. ⟨10.1016/j.ejca.2021.09.040⟩. ⟨hal-03622797⟩
  • Gayathri Devi, Pascal Finetti, Michael Morse, Seayoung Lee, Alexandre de Nonneville, et al.. Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy. Cancers, MDPI, 2021, 13 (11), pp.2807. ⟨10.3390/cancers13112807⟩. ⟨hal-03623076⟩
  • Florence Duffaud, Antoine Italiano, Emannuelle Bompas, Maria Rios, Nicolas Penel, et al.. Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. European Journal of Cancer, Elsevier, 2021, 150, pp.108-118. ⟨10.1016/j.ejca.2021.03.039⟩. ⟨hal-03623638⟩
  • Jean-Luc Raoul, Sandrine Oziel-Taieb, Thierry Lecomte, José Adelaide, Arnaud Guille, et al.. Case report: Two cases of metastatic pancreatoblastoma in adults: efficacy of Folfirinox and implication of the wnt/β-catenin pathway in genomic analysis. Frontiers in Oncology, Frontiers, 2021, 11, pp.1-8. ⟨10.3389/fonc.2021.564506⟩. ⟨hal-03623119⟩
  • Yohan Fayet, Raphaël Tétreau, Charles Honoré, Louis-Romée Le Nail, Cécile Dalban, et al.. Determinants of the access to remote specialised services provided by national sarcoma reference centres. BMC Cancer, BioMed Central, 2021, 21 (1), pp.631. ⟨10.1186/s12885-021-08393-4⟩. ⟨inserm-03243378⟩
  • Julie Delyon, Raphael Porcher, Maxime Battistella, Nicolas Meyer, Henri Adamski, et al.. A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans. Journal of Investigative Dermatology, Nature Publishing Group, 2021, 141 (4), pp.761-769.e2. ⟨10.1016/j.jid.2020.06.039⟩. ⟨hal-03623658⟩
  • Racha Fayad, Monserrat Vázquez Rojas, Mariagrazia Partisani, Pascal Finetti, Shiraz Dib, et al.. EFA6B regulates a stop signal for collective invasion in breast cancer. Nature Communications, Nature Publishing Group, 2021, 12, pp.2198. ⟨10.1038/s41467-021-22522-4⟩. ⟨hal-03434635⟩
  • F. Bertucci, Diana Bello, Alexandre Bertucci, Thibault de La Motte Rouge, Cyriac Blonz, et al.. Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA -mutant advanced breast cancer: Data from the French early access program.. Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (15_suppl), pp.1064-1064. ⟨10.1200/JCO.2021.39.15_suppl.1064⟩. ⟨hal-03623116⟩
  • David Birnbaum, Sebastian K.S. Begg, Pascal Finetti, Charles Vanderburg, Anupriya Kulkarni, et al.. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, American Association for Cancer Research, 2021, 27 (8), pp.2314-2325. ⟨10.1158/1078-0432.CCR-20-1039⟩. ⟨hal-03623108⟩
  • Emilly Villodre, Xiaoding Hu, Richard Larson, Pascal Finetti, Kristen Gomez, et al.. Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. Molecular Oncology, Elsevier, 2021, 15 (10), pp.2752-2765. ⟨10.1002/1878-0261.13074⟩. ⟨hal-03623121⟩
  • P. Pautier, A. Floquet, C. Chevreau, N. Penel, C. Guillemet, et al.. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery. ESMO Open, European Society for Medical Oncology, 2021, 6 (4), pp.100209. ⟨10.1016/j.esmoop.2021.100209⟩. ⟨hal-03623631⟩
  • Ke-Da yu, Xi-yu Liu, Li Chen, Miao Mo, Jiong Wu, et al.. Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial. The Lancet Regional Health - Western Pacific, 2021, 11, pp.100158. ⟨10.1016/j.lanwpc.2021.100158⟩. ⟨hal-03623636⟩
  • François Bertucci, Laurys Boudin, Pascal Finetti, Christophe van Berckelaer, Peter van Dam, et al.. Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. OncoImmunology, Taylor & Francis, 2021, 10 (1), ⟨10.1080/2162402X.2021.1929724⟩. ⟨hal-03583271⟩
  • Angélina Acier, Magali Godard, Fanny Gassiot, Pascal Finetti, Marion Rubis, et al.. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma.. Communications Biology, Nature Publishing Group, 2021, 4 (1), pp.987. ⟨10.1038/s42003-021-02508-0⟩. ⟨hal-03452855⟩
  • Guillaume Belthier, Zeinab Homayed, Fanny Grillet, Christophe Duperray, Julie Vendrell, et al.. CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM. Cancers, MDPI, 2021, 13 (19), pp.4966. ⟨10.3390/cancers13194966⟩. ⟨hal-03394453⟩
  • Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, et al.. 739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial. Annals of Oncology, Elsevier, 2021, 32 (15_suppl), pp.S737-S738. ⟨10.1016/j.annonc.2021.08.1181⟩. ⟨hal-03622737⟩
  • yuchen Guo, Monica Gabola, Rossano Lattanzio, Conception Paul, Valérie Pinet, et al.. Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer. Journal of Clinical Investigation, American Society for Clinical Investigation, 2021, 131 (4), ⟨10.1172/JCI131517⟩. ⟨hal-03152320⟩
  • Stéphane Fattori, Laurent Gorvel, Samuel Granjeaud, Philippe Rochigneux, Marie-Sarah Rouvière, et al.. Quantification of Immune Variables from Liquid Biopsy in Breast Cancer Patients Links Vδ2+ γδ T Cell Alterations with Lymph Node Invasion. Cancers, MDPI, 2021, 13 (3), pp.441. ⟨10.3390/cancers13030441⟩. ⟨hal-03152759⟩
  • Anthony Goncalves, Pascal Finetti, Daniel Birnbaum, F. Bertucci. The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer. npj Breast Cancer, Nature, 2021, 7 (1), pp.48. ⟨10.1038/s41523-021-00256-2⟩. ⟨hal-03623055⟩
  • François Bertucci, Steven Van Laere, Daniel Birnbaum. Genomic landscape of inflammatory breast cancer identifies potential actionable genetic alterations. Oncoscience, Impact Journals, 2020, 7 (7-8), pp.57-59. ⟨10.18632/oncoscience.515⟩. ⟨hal-03623667⟩
  • François Bertucci, Charlotte Rypens, Pascal Finetti, Arnaud Guille, José Adélaïde, et al.. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers. Molecular Oncology, Elsevier, 2020, 14 (3), pp.504-519. ⟨10.1002/1878-0261.12621⟩. ⟨hal-03623678⟩
  • Evodie Peperstraete, Clément Lecerf, Jordan Collette, Constance Vennin, Ludivine Raby, et al.. Enhancement of Breast Cancer Cell Aggressiveness by lncRNA H19 and its Mir-675 Derivative: Insight into Shared and Different Actions. Cancers, MDPI, 2020, 12 (7), pp.1730. ⟨10.3390/cancers12071730⟩. ⟨hal-02896573⟩
  • A. Takedachi, E. Despras, S. Scaglione, R. Guérois, J. Guervilly, et al.. Publisher Correction: SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations. Nature Structural and Molecular Biology, Nature Publishing Group, 2020, 27 (6), pp.604-604. ⟨10.1038/s41594-020-0447-z⟩. ⟨hal-02997075⟩
  • Maud Toulmonde, Carlo Lucchesi, Stéphanie Verbeke, Amandine Crombe, Julien Adam, et al.. High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. EBioMedicine, Elsevier, 2020, 62, ⟨10.1016/j.ebiom.2020.103131⟩. ⟨hal-03034609⟩
  • A. Takedachi, E. Despras, S. Scaglione, R. Guérois, J. Guervilly, et al.. SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations. Nature Structural and Molecular Biology, Nature Publishing Group, 2020, 27 (5), pp.438-449. ⟨10.1038/s41594-020-0419-3⟩. ⟨hal-03079782⟩
  • A Takedachi, E Despras, S Scaglione, R Guérois, J Guervilly, et al.. SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations.. Nature Structural and Molecular Biology, Nature Publishing Group, 2020, 27 (5), pp.438-449. ⟨10.1038/s41594-020-0419-3⟩. ⟨hal-03023347⟩
  • Charlotte Rypens, Melike Marsan, Christophe van Berckelaer, Charlotte Billiet, Kirsten Melis, et al.. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity. Breast Cancer Research and Treatment, Springer Verlag, 2020, 180 (2), pp.385-395. ⟨10.1007/s10549-020-05571-z⟩. ⟨hal-03623677⟩
  • Nicolas Penel, Olivier Mir, Jennifer Wallet, Isabelle Ray-Coquard, Axel Le Cesne, et al.. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. European Journal of Cancer, Elsevier, 2020, 126, pp.45-55. ⟨10.1016/j.ejca.2019.12.001⟩. ⟨hal-03623680⟩
  • François Richard, Samira Majjaj, David Venet, Françoise Rothé, Julien Pingitore, et al.. Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. Clinical Cancer Research, American Association for Cancer Research, 2020, 26 (23), pp.6254-6265. ⟨10.1158/1078-0432.ccr-20-2268⟩. ⟨hal-03623659⟩
  • David Birnbaum, Pascal Finetti, Daniel Birnbaum, F. Bertucci. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer—Letter. Clinical Cancer Research, American Association for Cancer Research, 2020, 26 (20), pp.5539-5539. ⟨10.1158/1078-0432.ccr-20-1969⟩. ⟨hal-03623653⟩
  • P. Pautier, N. Penel, I. Ray-Coquard, A. Italiano, E. Bompas, et al.. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study). European Journal of Cancer, Elsevier, 2020, 125, pp.31-37. ⟨10.1016/j.ejca.2019.10.028⟩. ⟨hal-02429038⟩
  • Toshiaki Iwase, Kenichi Harano, Hiroko Masuda, Kumiko Kida, Kenneth R Hess, et al.. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer, BioMed Central, 2020, 20 (1), pp.430. ⟨10.1186/s12885-020-06940-z⟩. ⟨inserm-02913696⟩
  • Bérengère Dadone-Montaudié, Audrey Laroche-Clary, Aline Mongis, Emmanuel Chamorey, Ilaria Di Mauro, et al.. Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting. Cancers, MDPI, 2020, 12, ⟨10.3390/cancers12103058⟩. ⟨hal-03034592⟩
  • Maud Maillard, Christine Chevreau, Félicien Le Louedec, Manon Cassou, Caroline Delmas, et al.. Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma. Cancers, MDPI, 2020, 12 (12), pp.3647. ⟨10.3390/cancers12123647⟩. ⟨hal-03623645⟩
  • Anaïs Aulas, Pascal Finetti, Shawn Lyons, François Bertucci, Daniel Birnbaum, et al.. Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?. Cancers, MDPI, 2020, 12 (9), pp.2470. ⟨10.3390/cancers12092470⟩. ⟨hal-03606494⟩
  • Francois Bertucci, Anne-Gaëlle Le Corroller-Soriano, Audrey Monneur, Sylvain Fluzin, Patrice Viens, et al.. Santé numérique et « cancer hors les murs », Big Data et intelligence artificielle. Bulletin du Cancer, John Libbey Eurotext, 2020, 107 (1), pp.102-112. ⟨10.1016/j.bulcan.2019.07.006⟩. ⟨hal-02505031⟩
  • Mabrouka Doghman-Bouguerra, Pascal Finetti, Nelly Durand, Ivy Zortéa S Parise, Silviu Sbiera, et al.. Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC. Cancers, MDPI, 2020, 12, ⟨10.3390/cancers12030689⟩. ⟨inserm-02508381⟩
  • Essia Mezni, Cécile Vicier, Mathilde Guerin, Renaud Sabatier, François Bertucci, et al.. New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?. Cancers, MDPI, 2020, 12 (6), pp.1573. ⟨10.3390/cancers12061573⟩. ⟨hal-03623669⟩
  • François Bertucci, Pascal Finetti, Anthony Goncalves, Daniel Birnbaum. The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype. npj Breast Cancer, Nature, 2020, 6 (1), pp.8. ⟨10.1038/s41523-020-0151-5⟩. ⟨hal-03623676⟩
  • Kim Honselmann, Pascal Finetti, David Birnbaum, Christian Monsalve, Ulrich Wellner, et al.. Neoplastic–Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Molecular Cancer Research, American Association for Cancer Research, 2020, 18 (12), pp.1889-1902. ⟨10.1158/1541-7786.mcr-20-0439⟩. ⟨hal-03623660⟩
  • Alexandre Bertucci, F. Bertucci, Christophe Zemmour, Florence Lerebours, Jean-yves Pierga, et al.. PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. Frontiers in Oncology, Frontiers, 2020, 10, ⟨10.3389/fonc.2020.575978⟩. ⟨hal-03623650⟩
  • Anthony Goncalves, Essia Mezni, F. Bertucci. Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results. Current Opinion in Oncology, Lippincott, Williams & Wilkins, 2020, 32 (6), pp.585-593. ⟨10.1097/cco.0000000000000680⟩. ⟨hal-03623648⟩
  • Anthony Gonçalves, Alexandre Bertucci, François Bertucci. PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?. Cancers, MDPI, 2020, 12 (6), pp.1378. ⟨10.3390/cancers12061378⟩. ⟨hal-03623672⟩
  • Mathias Neron, Christophe Sajous, Simon Thezenas, Sophie Piperno-Neumann, Fabien Reyal, et al.. Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study. Annals of Surgical Oncology, Springer Verlag, 2020, 27 (6), pp.1818-1827. ⟨10.1245/s10434-020-08217-y⟩. ⟨hal-03623684⟩
  • Guoqiang Hua, Aurélie Bergon, Pierre Cauchy, Brigitte Kahn‐perlès, François Bertucci, et al.. ERBB2b mRNA isoform encodes a nuclear variant of the ERBB2 oncogene in breast cancer. Journal of Cellular Biochemistry, Wiley, 2020, ⟨10.1002/jcb.29762⟩. ⟨hal-02897104⟩
  • Anaïs Aulas, Pascal Finetti, Shawn M Lyons, François Bertucci, Daniel Birnbaum, et al.. Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?. Cancers, MDPI, 2020, 12 (9), pp.2470. ⟨10.3390/cancers12092470⟩. ⟨hal-02958029⟩
  • A. Takedachi, E. Despras, S. Scaglione, R. Guérois, J. Guervilly, et al.. SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations. Nature Structural and Molecular Biology, Nature Publishing Group, 2020, 27 (5), pp.438-449. ⟨10.1038/s41594-020-0419-3⟩. ⟨hal-02995970⟩
  • Abir Arfaoui, Claire Rioualen, Violette Azzoni, Guillaume Pinna, Pascal Finetti, et al.. A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. EMBO Molecular Medicine, Wiley Open Access, 2019, 11 (10), pp.e9930. ⟨10.15252/emmm.201809930⟩. ⟨hal-02539524⟩
  • A. Le Cesne, P. Marec-Berard, J.-y. Blay, N. Gaspar, F. Bertucci, et al.. Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. European Journal of Cancer, Elsevier, 2019, 119, pp.151-157. ⟨10.1016/j.ejca.2019.07.018⟩. ⟨hal-02529696⟩
  • Marie Meurer, A. Floquet, I Ray-Coquard, F. Bertucci, M Auriche, et al.. Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group. International Journal of Gynecological Cancer, Lippincott, Williams & Wilkins, 2019, 29 (4), pp.691-698. ⟨10.1136/ijgc-2018-000064⟩. ⟨hal-02530373⟩
  • Romain Lévêque, Cyril Corbet, Léo Aubert, Matthieu Guilbert, Chann Lagadec, et al.. ProNGF increases breast tumor aggressiveness through functional association of TrkA with EphA2. Cancer Letters, Elsevier, 2019, 449, pp.196-206. ⟨10.1016/j.canlet.2019.02.019⟩. ⟨hal-02529705⟩
  • Roxane Mari, Emilie Mamessier, Eric Lambaudie, Magali Provansal, Daniel Birnbaum, et al.. Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. Cancers, MDPI, 2019, 11 (6), pp.774. ⟨10.3390/cancers11060774⟩. ⟨hal-03606425⟩
  • Emilien Billon, Pascal Finetti, Alexandre Bertucci, Patricia Niccoli, Daniel Birnbaum, et al.. PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. OncoImmunology, Taylor & Francis, 2019, 8 (11), pp.e1655362. ⟨10.1080/2162402X.2019.1655362⟩. ⟨hal-03606482⟩
  • Francois Bertucci, Anne-Gaëlle Le Corroller-Soriano, Audrey Monneur-Miramon, Jean-François Moulin, Sylvain Fluzin, et al.. Outpatient Cancer Care Delivery in the Context of E-Oncology: A French Perspective on “Cancer outside the Hospital Walls”. Cancers, MDPI, 2019, 11 (2), pp.219. ⟨10.3390/cancers11020219⟩. ⟨hal-02504845⟩
  • C. Honore, J.B. Delhorme, E. Nassif, M. Faron, G. Ferron, et al.. Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients. Surgical Oncology, Elsevier, 2019, 29, pp.107-112. ⟨10.1016/j.suronc.2019.04.002⟩. ⟨hal-02528457⟩
  • Sophie Piperno-Neumann, Isabelle Ray-Coquard, Bob-Valéry Occean, Valérie Laurence, Didier Cupissol, et al.. Results of API–AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome‐09 study. International Journal of Cancer, Wiley, 2019, 146 (2), pp.413-423. ⟨10.1002/ijc.32526⟩. ⟨hal-02530602⟩
  • Renaud Sabatier, Emmanuelle Charafe-Jauffret, Jean-yves Pierga, Hervé Curé, Eric Lambaudie, et al.. Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. Journal of Clinical Medicine Research, Elmer Press, 2019, 8 (5), pp.612. ⟨10.3390/jcm8050612⟩. ⟨hal-02145624⟩
  • Luc Camoin, Jean-Paul Borg, Avais M Daulat, Pascal Finetti, Diego R Revinski, et al.. ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer. British Journal of Cancer, Cancer Research UK, 2019, 120 (9), pp.931-940. ⟨10.1038/s41416-019-0448-z⟩. ⟨hal-02145896⟩
  • David Jérémie Birnbaum, Pascal Finetti, Daniel Birnbaum, Emilie Mamessier, Francois Bertucci. XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. Journal of Clinical Medicine, MDPI, 2019, 8 (5), pp.596. ⟨10.3390/jcm8050596⟩. ⟨hal-02509509⟩
  • Alexandre de Nonneville, Pascal Finetti, José Adelaïde, Eric Lambaudie, Patrice Viens, et al.. A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. Cancers, MDPI, 2019, 11 (8), pp.1158. ⟨10.3390/cancers11081158⟩. ⟨hal-02518929⟩
  • Renaud Sabatier, Marc Lopez, Arnaud Guille, Emilien Billon, Nadine Carbuccia, et al.. High Response to Cetuximab in a Patient With EGFR -Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer. JCO precision oncology, American Society of Clinical Oncology, 2019, pp.1-8. ⟨10.1200/po.18.00310⟩. ⟨hal-03623686⟩
  • Lorène Seguin, Max Chaffanet, Séverine Garnier, José Adélaïde, Nadine Carbuccia, et al.. Major Response to Carboplatin in a Patient With Metastatic Triple-Negative Breast Cancer With Somatic Mutation of BRCA1 and Loss of RAD51B. JCO precision oncology, American Society of Clinical Oncology, 2019, pp.1-9. ⟨10.1200/po.18.00362⟩. ⟨hal-03623688⟩
  • Maroua Manai, Syrine Abdeljaoued, Aïda Goucha, Olfa Adouni, Ilhem Bettaieb, et al.. MARCKS protein overexpression is associated with poor prognosis in male breast cancer. Cancer Biomarkers, IOS Press, 2019, 26 (4), pp.513-522. ⟨10.3233/CBM-190637⟩. ⟨hal-02530358⟩
  • Alexandre De Nonneville, Dominique Barbolosi, Maeva Andriantsoa, Raouf El-Cheikh, Florence Duffaud, et al.. Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin. Contemporary Southeast Asia, Taylor & Francis, 2019, 11 (3), pp.432. ⟨10.3390/cancers11030432⟩. ⟨hal-02461464⟩
  • Marguerite Tyran, Nadine Carbuccia, Séverine Garnier, Arnaud Guille, José Adelaïde, et al.. A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. Cancers, MDPI, 2019, 11 (5), pp.665. ⟨10.3390/cancers11050665⟩. ⟨hal-02533361⟩
  • Avais M Daulat, Pascal Finetti, Diego R Revinski, Mônica Silveira Wagner, Luc Camoin, et al.. ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer. British Journal of Cancer, Cancer Research UK, 2019, 120 (9), pp.931-940. ⟨10.1038/s41416-019-0448-z⟩. ⟨hal-02518543⟩
  • Clémence Basse, Antoine Italiano, Nicolas Penel, Olivier Mir, Claire Chemin, et al.. Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years. International Journal of Cancer, Wiley, 2019, 145 (8), pp.2135-2143. ⟨10.1002/ijc.32307⟩. ⟨hal-02504786⟩
  • Sylvain Garciaz, Lia N’guyen Dasi, Pascal Finetti, Christine Chevalier, Julien Vernerey, et al.. Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. Clinical Epigenetics, BioMed Central, 2019, 11 (1), ⟨10.1186/s13148-019-0738-6⟩. ⟨hal-02322283⟩
  • Shuichi Aoki, Koetsu Inoue, Sebastian Klein, Stefan Halvorsen, Jiang Chen, et al.. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. Cancers, MDPI, 2019, 11 (4), pp.497. ⟨10.3390/cancers11040497⟩. ⟨hal-03583447⟩
  • Emilien Billon, Pascal Finetti, Alexandre Bertucci, Patricia Niccoli, Daniel Birnbaum, et al.. PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. OncoImmunology, Taylor & Francis, 2019, 8 (11), pp.e1655362. ⟨10.1080/2162402X.2019.1655362⟩. ⟨hal-02509464⟩
  • Alexia Lopresti, Fabrice Malergue, François Bertucci, Maria Lucia Liberatoscioli, Séverine Garnier, et al.. Sensitive and easy screening for circulating tumor cells by flow cytometry. JCI Insight, American Society for Clinical Investigation, 2019, 4 (14), ⟨10.1172/jci.insight.128180⟩. ⟨hal-02529764⟩
  • François Bertucci, Anne-Gaëlle Le Corroller-Soriano, Audrey Monneur-Miramon, Jean-François Moulin, Sylvain Fluzin, et al.. Outpatient Cancer Care Delivery in the Context of E-Oncology: A French Perspective on “Cancer outside the Hospital Walls”. Cancers, MDPI, 2019, 11 (2), pp.219. ⟨10.3390/cancers11020219⟩. ⟨inserm-02329449⟩
  • Jessica Roelands, Wouter Hendrickx, Gabriele Zoppoli, Raghvendra Mall, Mohamad Saad, et al.. Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. Journal for Immunotherapy of Cancer, BMJ Publishing Group 2019, 8 (1), pp.e000617. ⟨10.1136/jitc-2020-000617⟩. ⟨hal-03623675⟩
  • Maud Toulmonde, Marina Pulido, Isabelle Ray-Coquard, Thierry André, Nicolas Isambert, et al.. Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. The Lancet Oncology, 2019, 20 (9), pp.1263-1272. ⟨10.1016/S1470-2045(19)30276-1⟩. ⟨hal-02533355⟩
  • Luc Xerri, José Adelaïde, Morgan Avenin, Arnaud Guille, Sébastien Taix, et al.. Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution. Histopathology, Wiley, 2019, 74 (4), pp.654-662. ⟨10.1111/his.13783⟩. ⟨hal-02533424⟩
  • yi Xiao, Ding Ma, Shen Zhao, Chen Suo, Jinxiu Shi, et al.. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. Clinical Cancer Research, American Association for Cancer Research, 2019, 25 (16), pp.5002-5014. ⟨10.1158/1078-0432.CCR-18-3524⟩. ⟨hal-02533431⟩
  • C. van Berckelaer, C. Rypens, P. van Dam, L. Pouillon, M. Parizel, et al.. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. Breast Cancer Research, BioMed Central, 2019, 21 (1), pp.28. ⟨10.1186/s13058-019-1108-1⟩. ⟨hal-02533387⟩
  • Francois Bertucci, Charlotte Ng, Anne Patsouris, Nathalie Droin, Salvatore Piscuoglio, et al.. Author Correction: Genomic characterization of metastatic breast cancers. Nature, Nature Publishing Group, 2019, 572 (7767), pp.E7-E7. ⟨10.1038/s41586-019-1380-3⟩. ⟨hal-02504834⟩
  • J.-y. Blay, C. Honore, E. Stoeckle, P. Méeus, M. Jafari, et al.. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Annals of Oncology, Elsevier, 2019, Annals of oncology official journal of the European Society for Medical Oncology, 30 (7), pp.1143-1153. ⟨10.1093/annonc/mdz124⟩. ⟨hal-02509515⟩
  • Maroua Manai, Raoudha Doghri, Pascal Finetti, Karima Mrad, Rihab Bouabsa, et al.. Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer. In Vivo, International Institute of Anticancer Research (IIAR), 2019, 34 (1), pp.177-184. ⟨10.21873/invivo.11759⟩. ⟨hal-03623682⟩
  • F. Bertucci, P. Finetti, A. Monneur, D. Birnbaum. Pathological grade-independent prediction of chemosensitivity by CINSARC should rehabilitate adjuvant chemotherapy in soft tissue sarcomas of any grade. Annals of Oncology, Elsevier, 2019, 30 (2), pp.342-343. ⟨10.1093/annonc/mdy528⟩. ⟨hal-02505000⟩
  • Alexandre Bertucci, Jérôme Guiramand, Lena Mescam, Audrey Monneur, Magali Bisbal, et al.. Successful Imatinib Treatment of an Abdominal Compartment Syndrome due to Huge Gastrointestinal Stromal Tumour. Case Reports in Oncology, Basel : Karger, 2019, 12 (2), pp.644-649. ⟨10.1159/000502338⟩. ⟨hal-02504820⟩
  • Gabrielle Planes-Laine, Philippe Rochigneux, François Bertucci, Anne-Sophie Chrétien, Patrice Viens, et al.. PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. Cancers, MDPI, 2019, 11 (7), pp.1033. ⟨10.3390/cancers11071033⟩. ⟨hal-02533030⟩
  • Christine Desmedt, Julien Pingitore, Françoise Rothé, Caterina Marchio, Florian Clatot, et al.. ESR1 mutations in metastatic lobular breast cancer patients. npj Breast Cancer, Nature, 2019, 5 (1), ⟨10.1038/s41523-019-0104-z⟩. ⟨hal-02352890⟩
  • Francois Bertucci, Charlotte Ng, Anne Patsouris, Nathalie Droin, Salvatore Piscuoglio, et al.. Genomic characterization of metastatic breast cancers. Nature, Nature Publishing Group, 2019, 569 (7757), pp.560-564. ⟨10.1038/s41586-019-1056-z⟩. ⟨hal-02504838⟩
  • Mathias Neron, Christophe Sajous, Simon Thezenas, Sophie Piperno-Neumann, Fabien Reyal, et al.. Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study. Annals of Surgical Oncology, Springer Verlag, 2019, ⟨10.1245/s10434-019-08097-x⟩. ⟨hal-02530556⟩
  • Roxane Mari, Emilie Mamessier, Eric Lambaudie, Magali Provansal, Daniel Birnbaum, et al.. Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. Cancers, MDPI, 2019, 11 (6), pp.774. ⟨10.3390/cancers11060774⟩. ⟨hal-02152656⟩
  • Francois Bertucci, Pascal Finetti, Audrey Monneur, Delphine Perrot, Christine Chevreau, et al.. PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target. Molecular Oncology, Elsevier, 2019, 13 (7), pp.1577-1588. ⟨10.1002/1878-0261.12522⟩. ⟨hal-02504850⟩
  • Abdallah  Al farai, Lénaïg Mescam, Valeria De luca, Audrey Monneur, Delphine Perrot, et al.. Giant Pedunculated Hepatic Hemangioma: A Case Report and Literature Review. Case Reports in Oncology, Basel : Karger, 2018, 11 (2), pp.476-484. ⟨10.1159/000490696⟩. ⟨hal-03623704⟩
  • Emilien Billon, Anne-Marie Stoppa, Lena Mescam, Massimo Bocci, Audrey Monneur, et al.. Reversible rituximab-induced rectal Kaposi's sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma. CLINICAL SARCOMA RESEARCH, 2018, 8, ⟨10.1186/s13569-018-0097-7⟩. ⟨hal-02143666⟩
  • Emmanuelle Charafe-Jauffret, Julien Wicinski, Olivier Cabaud, Marc Lopez, Stephane Audebert, et al.. Ex vivo CSC assays for personalized testing of drug susceptibility in advanced breast cancer. CANCER RESEARCH, 2018, 78 (4, S). ⟨hal-02143678⟩
  • Marie Cantaloube, Laurence Moureau-Zabotto, Lena Mescam, Audrey Monneur, Valeria Deluca, et al.. Metastatic Intimal Sarcoma of the Pulmonary Artery Sensitive to Carboplatin-Vinorelbine Chemotherapy: Case Report and Literature Review. Case Reports in Oncology, Basel : Karger, 2018, 11 (1), pp.21-28. ⟨10.1159/000485740⟩. ⟨hal-02143619⟩
  • F Bertucci, A de Nonneville, P Finetti, D Perrot, M Nilbert, et al.. The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma. Annals of Oncology, Elsevier, 2018, 29 (2), pp.459 - 465. ⟨10.1093/annonc/mdx699⟩. ⟨hal-01787485⟩
  • Olivier Bouché, Axel Le Cesne, Maria Rios, Loic Chaigneau, Antoine Italiano, et al.. EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib. PLoS ONE, Public Library of Science, 2018, 13 (9), pp.e0204117. ⟨10.1371/journal.pone.0204117⟩. ⟨hal-02005925⟩
  • Raoudha Boughzala-Bennadji, Eberhard Stoeckle, Cécile Le Péchoux, Pierre Méeus, Charles Honoré, et al.. Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy. International Journal of Radiation Oncology - Biology - Physics, Elsevier, 2018, 102 (2), pp.399-406. ⟨10.1016/j.ijrobp.2018.05.055⟩. ⟨hal-02049039⟩
  • Renaud Sabatier, Véronique Diéras, Xavier B. Pivot, Etienne Brain, Henri Roche, et al.. Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer. Breast Cancer Research and Treatment, Springer Verlag, 2018, 50 (4), pp.1226-1237. ⟨10.4143/crt.2017.446⟩. ⟨inserm-01985845⟩
  • Christine Desmedt, Roberto Salgado, Marco Fornili, Giancarlo Pruneri, Gert van den Eynden, et al.. Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. European Journal of Cancer, Elsevier, 2018, 99 (7), pp.28-36. ⟨10.1016/j.ejca.2018.05.008⟩. ⟨hal-03623702⟩
  • Audrey Monneur, Anthony Goncalves, Francois Bertucci. PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer. Bulletin du Cancer, John Libbey Eurotext, 2018, 105 (3), pp.261-272. ⟨10.1016/j.bulcan.2017.11.012⟩. ⟨hal-02143676⟩
  • L. Seguin, M. Chaffanet, R. Sabatier, A. Jose, S. Garnier, et al.. A major response to carboplatin in a metastatic triple-negative breast cancer patient with somatic mutation of BRCA1 and RAD51B: When chemotherapy meets precision medicine. Annals of Oncology, Elsevier, 2018, 29 (6), ⟨10.1093/annonc/mdy314.030⟩. ⟨hal-02143656⟩
  • Alexandre de Nonneville, François Bertucci, Pascal Finetti, D. Perrot, M. Nilbert, et al.. Determinants of favorable or unfavorable opinion about euthanasia in a sample of French cancer patients receiving palliative care. BMC Palliative Care, BioMed Central, 2018, 17 (1), pp.104. ⟨10.1186/s12904-018-0357-6⟩. ⟨hal-03583406⟩
  • Emilie Mamessier, David Birnbaum, Pascal Finetti, Daniel Birnbaum, François Bertucci. CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors. Annals of translational medicine, AME Publishing Company, 2018, 6 (3), pp.54 - 54. ⟨10.21037/atm.2017.11.26⟩. ⟨hal-01765411⟩
  • Raoudha Doghri, Maroua Manai, Pascal Finetti, Maha Driss, Emilie Agavnian, et al.. Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value. International Journal of Molecular Sciences, MDPI, 2018, 19 (1), ⟨10.3390/ijms19010041⟩. ⟨hal-02143620⟩
  • Loïc Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, Isabelle Ray-Coquard, Axel Le Cesne, et al.. Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial. BMC Cancer, BioMed Central, 2018, 18 (1), pp.963. ⟨10.1186/s12885-018-4828-1⟩. ⟨inserm-02050851⟩
  • Mathilde Guérin, Anthony Gonçalves, yves Toiron, Emilie Baudelet, Matthieu Pophillat, et al.. Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. Oncotarget, Impact journals, 2018, 9 (73), pp.33762-33777. ⟨10.18632/oncotarget.26031⟩. ⟨hal-02145636⟩
  • Francois Bertucci, Pascal Finetti, Alexandre de Nonneville, Daniel Birnbaum. ``Wnt/beta-Catenin in GIST''-Letter. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (1), pp.327-328. ⟨10.1158/1535-7163.MCT-17-0948⟩. ⟨hal-02143618⟩
  • Maroua Manai, Pascal Finetti, Nesrine Mejri, Salma Athimni, Daniel Birnbaum, et al.. Inflammatory breast cancer in 210�patients: A retrospective study on epidemiological, anatomo‑clinical features and therapeutic results. Molecular and Clinical Oncology, Spandidos Publications, 2018, 10 (2), pp.223-230. ⟨10.3892/mco.2018.1773⟩. ⟨hal-02530356⟩
  • François Bertucci, Pascal Finetti, Ines Simeone, Wouter Hendrickx, Ena Wang, et al.. The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. British Journal of Cancer, Cancer Research UK, 2018, 119 (11), pp.1383-1391. ⟨10.1038/s41416-018-0309-1⟩. ⟨hal-03606514⟩
  • Emanuel Nicolas, Francois Bertucci, Renaud Sabatier, Anthony Goncalves. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. Cancers, MDPI, 2018, 10 (12), ⟨10.3390/cancers10120506⟩. ⟨hal-02143625⟩
  • Brice Chanez, Max Chaffanet, José Adélaide, Jeanne Thomassin, Séverine Garnier, et al.. Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer. JCO precision oncology, American Society of Clinical Oncology, 2018, pp.1-8. ⟨10.1200/po.18.00083⟩. ⟨hal-03623699⟩
  • Kenichi Harano, ying Wang, Bora Lim, Robert S. Seitz, Stephan W. Morris, et al.. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. PLoS ONE, Public Library of Science, 2018, 13 (10), pp.e0204513. ⟨10.1371/journal.pone.0204513⟩. ⟨hal-02143557⟩
  • David Birnbaum, François Bertucci, Pascal Finetti, Daniel Birnbaum, Emilie Mamessier. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Elsevier, 2018, 1869 (2), pp.248-255. ⟨10.1016/j.bbcan.2018.02.001⟩. ⟨hal-03583468⟩
  • Luc Xerri, José Adelaïde, Cornel Popovici, Séverine Garnier, Arnaud Guille, et al.. CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors. American Journal of Surgical Pathology, Lippincott, Williams & Wilkins, 2018, 42 (2), pp.150 - 159. ⟨10.1097/PAS.0000000000000989⟩. ⟨hal-01788565⟩
  • Emanuel Nicolas, François Bertucci, Renaud Sabatier, Anthony Gonçalves. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. Cancers, MDPI, 2018, 10 (12), pp.506. ⟨10.3390/cancers10120506⟩. ⟨hal-03669695⟩
  • Leonor Lopez Almeida, Michael Sebbagh, Francois Bertucci, Pascal Finetti, Julien Wicinski, et al.. The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/beta-Catenin Signaling. Stem Cell Reports, Elsevier, 2018, 11 (5), pp.1040-1050. ⟨10.1016/j.stemcr.2018.09.008⟩. ⟨hal-02143631⟩
  • Nuria Kotecki, Axel Le Cesne, Emmanuelle Tresch-Bruneel, Isabelle Ray-Coquard, Christine Chevreau, et al.. Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma. American Journal of Clinical Oncology, Lippincott, Williams & Wilkins, 2018, 41 (11), pp.1094-1100. ⟨10.1097/coc.0000000000000430⟩. ⟨hal-03623697⟩
  • Francois Bertucci, Pascal Finetti, Ines Simeone, Wouter Hendrickx, Ena Wang, et al.. The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. Breast Cancer Research and Treatment, Springer Verlag, 2018, 119 (11), pp.1383-1391. ⟨10.1038/s41416-018-0309-1⟩. ⟨hal-02143596⟩
  • Wendy Woodward, Massimo Cristofanilli, Sofia Merajver, Steven van Laere, Lajos Pusztai, et al.. Scientific summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) program 10th Anniversary Conference. Journal of Cancer, 2017, 8 (17), pp.3607-3614. ⟨10.7150/jca.21200⟩. ⟨hal-03623708⟩
  • M. M-Rabet, O. Cabaud, E. Josselin, P. Finetti, R. Castellano, et al.. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Annals of Oncology, Elsevier, 2017, ⟨10.1093/annonc/mdw678⟩. ⟨hal-01787533⟩
  • A. de Nonneville, A. Goncalves, C. Zemmour, M. Cohen, J.M. Classe, et al.. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study. European Journal of Cancer, Elsevier, 2017, 84, pp.34-43. ⟨10.1016/j.ejca.2017.06.043⟩. ⟨hal-02282824⟩
  • Audrey Monneur, Anthony Gonçalves, Marine Gilabert, Pascal Finetti, Carole Tarpin, et al.. Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers. Oncotarget, Impact journals, 2017, 8 (39), pp.66019 - 66032. ⟨10.18632/oncotarget.19732⟩. ⟨inserm-01984755⟩
  • Alexandre de Nonneville, Anthony Gonçalves, Christophe Zemmour, Jean Classe, Monique Cohen, et al.. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. Breast Cancer Research and Treatment, Springer Verlag, 2017, 162 (2), pp.307-316. ⟨10.1007/s10549-017-4136-5⟩. ⟨hal-03623719⟩
  • Mathilde Guerin, Keyvan Rezai, Nicolas Isambert, Mario Campone, Aurélie Autret, et al.. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. European Journal of Cancer, Elsevier, 2017, 86, pp.28-36. ⟨10.1016/j.ejca.2017.08.025⟩. ⟨hal-03623711⟩
  • Loïc Lebellec, Bruno Chauffert, Jean-yves Blay, Axel Le Cesne, Christine Chevreau, et al.. Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). European Journal of Cancer, Elsevier, 2017, 79, pp.119 - 128. ⟨10.1016/j.ejca.2017.03.037⟩. ⟨hal-01655981⟩
  • François Bertucci, Anthony Gonçalves. Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Current Oncology Reports, Current Medicine Group, 2017, 19 (10), pp.64. ⟨10.1007/s11912-017-0627-0⟩. ⟨hal-03623712⟩
  • Anthony Gonçalves, Audrey Monneur, Patrice Viens, François Bertucci. The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?. Expert Review of Anticancer Therapy, Expert Reviews (formerly Future Drugs), 2017, 17 (7), pp.593-606. ⟨10.1080/14737140.2017.1330655⟩. ⟨hal-03623715⟩
  • François Bertucci, Pascal Finetti, Delphine Perrot, Agnès Leroux, Françoise Collin, et al.. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. OncoImmunology, Taylor & Francis, 2017, 6 (3), pp.e1278100. ⟨10.1080/2162402X.2016.1278100⟩. ⟨hal-01765418⟩
  • Manel M 'Rabet, François Bertucci, Daniel Birnbaum, Marc Lopez. Nectine-4 : un biomarqueur pronostique et une cible thérapeutique potentielle dans le cancer du sein triple-négatif . médecine/sciences, EDP Sciences, 2017. ⟨hal-01788721⟩
  • J-y Pierga, F-C Bidard, A. Autret, T. Petit, F. André, et al.. Circulating Tumour Cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Annals of Oncology, Elsevier, 2017, 28, pp.mdw535. ⟨10.1093/annonc/mdw535⟩. ⟨inserm-01985299⟩
  • David Birnbaum, Pascal Finetti, Alexia Lopresti, Marine Gilabert, Flora Poizat, et al.. A 25-gene classifier predicts overall survival in resectable pancreatic cancer. BMC Medicine, BioMed Central, 2017, 15 (1), ⟨10.1186/s12916-017-0936-z⟩. ⟨hal-01787872⟩
  • Madhura Joglekar-Javadekar, Steven van Laere, Michael Bourne, Manal Moalwi, Pascal Finetti, et al.. Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC). Neoplasia, Elsevier, 2017, 19 (7), pp.564-573. ⟨10.1016/j.neo.2017.03.002⟩. ⟨hal-01789694⟩
  • François Bertucci, David Birnbaum, Pascal Finetti, Marine Gilabert, Flora Poizat, et al.. Prognostic Value of Molecular Subtypes in Pancreatic Cancer. Pancreas, 2017, 46 (4), pp.e29-e31. ⟨10.1097/MPA.0000000000000787⟩. ⟨hal-03606452⟩
  • Brice Chanez, François Bertucci, Marine Gilabert, Anne Madroszyk, Frédérique Rousseau, et al.. A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study. Supportive Care in Cancer, Springer Verlag (Germany), 2017, 25 (9), pp.2715-2722. ⟨10.1007/s00520-017-3680-1⟩. ⟨hal-03623718⟩
  • Philippe Rochigneux, Lénaig Mescam-Mancini, Delphine Perrot, Erwan Bories, Laurence Moureau-Zabotto, et al.. Gastrointestinal Stromal Tumour with Synchronous Bone Metastases: A Case Report and Literature Review. Case Reports in Oncology, Basel : Karger, 2017, 10 (1), pp.66-76. ⟨10.1159/000455188⟩. ⟨hal-03623722⟩
  • Pauline Rochefort, Antoine Italiano, Valérie Laurence, Nicolas Penel, Audrey Lardy-Cleaud, et al.. A retrospective multicentric study of ewing sarcoma family of tumors in patients older than 50: management and outcome. Scientific Reports, Nature Publishing Group, 2017, Scientific reports, 7, ⟨10.1038/s41598-017-17733-z⟩. ⟨hal-02613645⟩
  • Vincent Berry, Laurent Basson, Emilie Bogart, Olivier Mir, Jean-yves Blay, et al.. Regosarc: regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-a quality-adjusted time without symptoms of progression or toxicity analysis. Cancer, Wiley, 2017, Cancer, 123, pp.2294-2302. ⟨10.1002/cncr.30661⟩. ⟨hal-02638646⟩
  • François Bertucci, Pascal Finetti, Daniel Birnbaum. Wnt Signaling Inhibition Promotes Apoptosis in Sarcomas—Letter. Molecular Cancer Therapeutics, American Association for Cancer Research, 2017, 16 (10), pp.2324 - 2324. ⟨10.1158/1535-7163.MCT-17-0491⟩. ⟨hal-01787271⟩
  • Rita El Helou, Guillaume Pinna, Olivier Cabaud, Julien Wicinski, Ricky Bhajun, et al.. miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling. Cell Reports, Elsevier Inc, 2017, 18 (9), pp.2256-2268. ⟨10.1016/j.celrep.2017.02.016⟩. ⟨hal-01789620⟩
  • S. Salas, N. Resseguier, J. y. Blay, A. Le Cesne, A. Italiano, et al.. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. Annals of Oncology, Elsevier, 2017, 28 (8), pp.1979 - 1987. ⟨10.1093/annonc/mdx250⟩. ⟨hal-01655970⟩
  • Anne Morel, Christophe Ginestier, Roxane Pommier, Olivier Cabaud, Emmanuelle Ruiz, et al.. A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stability. Nature Medicine, Nature Publishing Group, 2017, 23 (5), pp.568 - 578. ⟨10.1038/nm.4323⟩. ⟨hal-01788395⟩
  • Ruth Rodriguez-Barrueco, Erin A Nekritz, François Bertucci, Jiyang yu, Felix Sanchez-Garcia, et al.. miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes and Development, Cold Spring Harbor Laboratory Press, 2017, 31 (6), pp.553-566. ⟨10.1101/gad.292318.116⟩. ⟨hal-01787959⟩
  • Maroua Manai, Jeanne Thomassin-Piana, Amor Gamoudi, Pascal Finetti, Marc Lopez, et al.. MARCKS protein overexpression in inflammatory breast cancer. Oncotarget, Impact journals, 2017, 8, pp.6246 - 6257. ⟨10.18632/oncotarget.14057⟩. ⟨hal-01787705⟩
  • François Bertucci, Max Chaffanet, Daniel Birnbaum. An ICGC major achievement in breast cancer: a comprehensive catalog of mutations and mutational signatures. Chinese Clinical Oncology, AME Publishing Company, 2017, 6 (1), pp.4 - 4. ⟨10.21037/cco.2016.11.01⟩. ⟨hal-01787356⟩
  • Wouter Hendrickx, Ines Simeone, Samreen Anjum, younes Mokrab, François Bertucci, et al.. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. OncoImmunology, Taylor & Francis, 2017, 6 (2), ⟨10.1080/2162402X.2016.1253654⟩. ⟨hal-01788951⟩
  • Laurys Boudin, Christian Chabannon, Patrick Sfumato, Renaud Sabatier, François Bertucci, et al.. [Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].. Bulletin du Cancer, John Libbey Eurotext, 2017, 104 (4), pp.332 - 343. ⟨10.1016/j.bulcan.2016.12.007⟩. ⟨hal-01788977⟩
  • David Birnbaum, Pascal Finetti, Daniel Birnbaum, Emilie Mamessier, François Bertucci. Validation and comparison of the molecular classifications of pancreatic carcinomas. Molecular Cancer, BioMed Central, 2017, 16 (1), pp.168. ⟨10.1186/s12943-017-0739-z⟩. ⟨hal-03583469⟩
  • Preeti Putcha, Jiyang yu, Ruth Rodriguez-Barrueco, Laura Saucedo-Cuevas, Patricia Villagrasa, et al.. Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Research, BioMed Central, 2017, 19 (1), pp.49. ⟨10.1186/s13058-017-0841-6⟩. ⟨hal-03623716⟩
  • Nicolas Penel, Axel Le Cesne, Sylvie Bonvalot, Antoine Giraud, Emmanuelle Bompas, et al.. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. European Journal of Cancer, Elsevier, 2017, 83, pp.125-131. ⟨10.1016/j.ejca.2017.06.017⟩. ⟨hal-03623713⟩
  • François Bertucci, Anthony Goncalves, Patrice Viens. Bevacizumab in HER2-negative inflammatory breast cancer. Oncoscience, Impact Journals, 2016, 3 (11-12), pp.297-298. ⟨10.18632/oncoscience.324⟩. ⟨hal-03623723⟩
  • Olivier Mir, Claire Cropet, Maud Toulmonde, Axel Le Cesne, Mathieu Molimard, et al.. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncology, Elsevier, 2016, 17 (5), pp.632-641. ⟨10.1016/s1470-2045(16)00075-9⟩. ⟨hal-03623734⟩
  • David Birnbaum, François Bertucci, Pascal Finetti, José Adélaïde, Marc Giovannini, et al.. Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma.. Cancer Genomics and Proteomics, International Institute of Anticancer Research, 2016, 13 (3), pp.191-200. ⟨hal-03583479⟩
  • N. Penel, J.M. Coindre, S. Bonvalot, A. Italiano, A. Neuville, et al.. Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. European Journal of Cancer, Elsevier, 2016, 58, pp.90--96. ⟨10.1016/j.ejca.2016.02.008⟩. ⟨hal-01812682⟩
  • David Birnbaum, Pascal Finetti, Alexia Lopresti, Marine Gilabert, Flora Poizat, et al.. Prognostic value of PDL1 expression in pancreatic cancer. Oncotarget, Impact journals, 2016, 7 (44), pp.71198-71210. ⟨10.18632/oncotarget.11685⟩. ⟨hal-03583475⟩
  • Emeline Tabouret, François Bertucci, Jean-yves Pierga, Thierry Petit, Christelle Levy, et al.. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget, Impact journals, 2016, 7 (14), pp.18531-18540. ⟨10.18632/oncotarget.7612⟩. ⟨hal-03623733⟩
  • Julie Giraud, Laura Failla, Jean-Marc Pascussi, Ebba Louise Lagerqvist, Jérémy Ollier, et al.. Autocrine Secretion of Progastrin Promotes the Survival and Self-Renewal of Colon Cancer Stem-like Cells. Cancer Research, American Association for Cancer Research, 2016, 76 (12), pp.3618 - 3628. ⟨10.1158/0008-5472.CAN-15-1497⟩. ⟨hal-01905320⟩
  • Laurys Boudin, Anthony Gonçalves, Patrick Sfumato, Renaud Sabatier, François Bertucci, et al.. Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study. American Journal of Cancer, Adis, 2016, 7 (14), pp.2077-2084. ⟨10.7150/jca.15797⟩. ⟨inserm-01987531⟩
  • Tania M. Puvirajesinghe, François Bertucci, Ashish Jain, Pierluigi Scerbo, Edwige Belotti, et al.. Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2–JNK signalling in breast cancer. Nature Communications, Nature Publishing Group, 2016, 7, pp.10318. ⟨10.1038/ncomms10318⟩. ⟨hal-01447570⟩
  • François Bertucci, Pascal Finetti, Arnaud Guille, José Adélaïde, Séverine Garnier, et al.. Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget, Impact journals, 2016, 7 (19), pp.27208-27219. ⟨10.18632/oncotarget.8349⟩. ⟨hal-03623731⟩
  • Christelle Vincent-Fabert, Nadine Platet, Amelle Vandevelde, Mathilde Poplineau, Myriam Koubi, et al.. PLZF mutation alters mouse hematopoietic stem cell function and cell cycle progression. Blood, American Society of Hematology, 2016, 127 (15), pp.1881-1885. ⟨10.1182/blood-2015-09-666974⟩. ⟨hal-03623736⟩
  • Laurys Boudin, Christian Chabannon, Patrick Sfumato, Renaud Sabatier, François Bertucci, et al.. Corrigendum to “Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation” [Eur J Cancer 57 (April 2016) 118–126]. European Journal of Cancer, Elsevier, 2016, 67, pp.223. ⟨10.1016/j.ejca.2016.09.002⟩. ⟨hal-03623727⟩
  • François Bertucci, Mahmoud Fekih, Aurélie Autret, Thierry Petit, Florence Dalenc, et al.. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. Lancet Oncology, Elsevier, 2016, 17 (5), pp.600-611. ⟨10.1016/s1470-2045(16)00011-5⟩. ⟨hal-03623735⟩
  • David Birnbaum, Pascal Finetti, Alexia Lopresti, Marine Gilabert, Flora Poizat, et al.. Prognostic value of PDL1 expression in pancreatic cancer. Oncotarget, Impact journals, 2016, 7 (44), ⟨10.18632/oncotarget.11685⟩. ⟨hal-01765421⟩
  • François Bertucci, Patrice Viens, Daniel Birnbaum. SPAG5: the ultimate marker of proliferation in early breast cancer?. Lancet Oncology, Elsevier, 2016, 17 (7), pp.863-865. ⟨10.1016/s1470-2045(16)30092-4⟩. ⟨hal-03623730⟩
  • Chris Planque, Fatemeh Rajabi, Fanny Grillet, Pascal Finetti, François Bertucci, et al.. Pregnane X-receptor promotes stem cell-mediated colon cancer relapse. Oncotarget, Impact journals, 2016, 7 (35), pp.56558-56573. ⟨10.18632/oncotarget.10646⟩. ⟨hal-01431926⟩
  • Olivier Mir, Thomas Brodowicz, Antoine Italiano, Jennifer Wallet, Jean-yves Blay, et al.. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, Elsevier, 2016, 17 (12), pp.1732-1742. ⟨10.1016/s1470-2045(16)30507-1⟩. ⟨hal-03623726⟩
  • Avais M Daulat, François Bertucci, Stéphane Audebert, Arnauld Sergé, Pascal Finetti, et al.. PRICKLE1 contributes to cancer cell dissemination through its interaction with mTORC2 . Developmental Cell, Elsevier, 2016, pp.311-325. ⟨10.1016/j.devcel.2016.04.011⟩. ⟨hal-01321061⟩
  • Loic Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, Emmanuelle Bompas, yves Toiron, et al.. Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO). Oncotarget, Impact journals, 2016, Oncotarget, 7 (45), pp.73984-73994. ⟨10.18632/oncotarget.12172⟩. ⟨hal-01453300⟩
  • François Bertucci, Pascal Finetti, Daniel Birnbaum. XPO1, therapeutic...and prognostic target in sarcomas. Oncoscience, Impact Journals, 2016, 3 (5-6), pp.143-144. ⟨10.18632/oncoscience.304⟩. ⟨hal-03623732⟩
  • Christine Desmedt, Gabriele Zoppoli, Gunes Gundem, Giancarlo Pruneri, Denis Larsimont, et al.. Genomic Characterization of Primary Invasive Lobular Breast Cancer. Journal of Clinical Oncology, American Society of Clinical Oncology, 2016, 34 (16), pp.1872-1881. ⟨10.1200/jco.2015.64.0334⟩. ⟨hal-03623737⟩
  • Anthony Gonçalves, François Bertucci, Arnaud Guille, Severine Garnier, José Adelaide, et al.. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. Oncotarget, Impact journals, 2016, 7 (48), pp.79428-79441. ⟨10.18632/oncotarget.12714⟩. ⟨hal-03623724⟩
  • A. Patrikidou, J. Domont, Sylvie Chabaud, Isabelle Ray-Coquard, J.M. Coindre, et al.. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. European Journal of Cancer, Elsevier, 2016, 52, pp.173--180. ⟨10.1016/j.ejca.2015.10.069⟩. ⟨hal-01812685⟩
  • Loic Lebellec, Axel Le Cesne, Nicolas Penel, Jean -yves Blay, Christine Chevreau, et al.. Molecular targeted therapies (MTT) in advanced chordoma (AC) patients (pts).. Journal of clinical oncology, 2016, 34 (15, S), ⟨10.1200/JCO.2016.34.15\_suppl.11020⟩. ⟨hal-03598684⟩
  • Andrea Remo, Ines Simeone, Massimo Pancione, Pietro Parcesepe, Pascal Finetti, et al.. Systems biology analysis of gene expression data and gene network reverse-engineering approaches reveal NFAT5 as a candidate biomarker in Inflammatory Breast Cancer. Journal for Immunotherapy of Cancer, BMJ Publishing Group 2015, 3 (Suppl 1), pp.P6. ⟨10.1186/2051-1426-3-s1-p6⟩. ⟨hal-03623751⟩
  • Jennifer Allensworth, Myron Evans, François Bertucci, Amy Aldrich, Richard Festa, et al.. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. Molecular Oncology, Elsevier, 2015, 9 (6), pp.1155-1168. ⟨10.1016/j.molonc.2015.02.007⟩. ⟨hal-03623746⟩
  • Renaud Sabatier, Pascal Finetti, Emilie Mamessier, José Adelaide, Max Chaffanet, et al.. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget, Impact journals, 2015, 6 (7), pp.5449-5464. ⟨10.18632/oncotarget.3216⟩. ⟨hal-03583484⟩
  • Constance Vennin, Nathalie Spruyt, Fatima Dahmani, Sylvain Julien, François Bertucci, et al.. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget, Impact journals, 2015, 6 (30), ⟨10.18632/oncotarget.4976⟩. ⟨hal-02347866⟩
  • Isabelle Ray-Coquard, Julien Domont, Emmanuelle Tresch-Bruneel, Emmanuelle Bompas, Philippe Cassier, et al.. Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. Journal of Clinical Oncology, American Society of Clinical Oncology, 2015, 33 (25), pp.2797-2802. ⟨10.1200/jco.2015.60.8505⟩. ⟨hal-03623742⟩
  • François Bertucci, Pascal Finetti, Daniel Birnbaum, Emilie Mamessier. The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers. OncoImmunology, Taylor & Francis, 2015, 5 (3), pp.e1085148. ⟨10.1080/2162402X.2015.1085148⟩. ⟨hal-03583477⟩
  • Christophe Zemmour, Francois Bertucci, Pascal Finetti, Bernard Chetrit, Daniel Birnbaum, et al.. Prediction of Early Breast Cancer Metastasis from DNA Microarray Data Using High-Dimensional Cox Regression Models. Cancer Informatics, Libertas Academica, 2015, 14(Suppl 2), pp.129-138. ⟨10.4137/cin.s17284⟩. ⟨inserm-01996812⟩
  • François Bertucci, Pascal Finetti, Daniel Birnbaum. The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy. Breast Cancer Research, BioMed Central, 2015, 17 (1), pp.54. ⟨10.1186/s13058-015-0559-2⟩. ⟨hal-03623743⟩
  • Léo Aubert, Matthieu Guilbert, Cyril Corbet, Elisabeth Génot, Eric Adriaenssens, et al.. NGF-induced TrkA/CD44 association is involved in tumor aggressiveness and resistance to lestaurtinib. Oncotarget, Impact journals, 2015, 6 (12), pp.9807-9819. ⟨10.18632/oncotarget.3227⟩. ⟨hal-03623750⟩
  • Preeti Putcha, Jiyang yu, Ruth Rodriguez-Barrueco, Laura Saucedo-Cuevas, Patricia Villagrasa, et al.. HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Research, BioMed Central, 2015, 17 (1), pp.149. ⟨10.1186/s13058-015-0658-0⟩. ⟨inserm-01254136⟩
  • Marie-Eve Rouge-Bugat, Donia Lassoued, Joy Bacrie, Nathalie Boussier, Jean-Pierre Delord, et al.. Guideline sheets on the side effects of anticancer drugs are useful for general practitioners. Supportive Care in Cancer, Springer Verlag (Germany), 2015, pp.3473 - 3480. ⟨10.1007/s00520-015-2705-x⟩. ⟨hal-01914751⟩
  • François Bertucci, Pascal Finetti, Emilie Mamessier, Maria Abbondanza Pantaleo, Annalisa Astolfi, et al.. PDL1 expression is an independent prognostic factor in localized GIST. OncoImmunology, Taylor & Francis, 2015, 4 (5), pp.e1002729. ⟨10.1080/2162402X.2014.1002729⟩. ⟨hal-03583480⟩
  • Maurice P.H.M. Jansen, Leen Sas, Anieta Sieuwerts, Caroline van Cauwenberghe, Diana Ramirez-Ardila, et al.. Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. Molecular Oncology, Elsevier, 2015, 9 (6), pp.1218-1233. ⟨10.1016/j.molonc.2015.02.006⟩. ⟨hal-03623744⟩
  • François Bertucci, Marjorie Faure, Maria-Rosa Ghigna, Bruno Chetaille, Jérôme Guiramand, et al.. High-grade soft tissue sarcoma arising in a desmoid tumor: case report and review of the literature. Clinical Sarcoma Research, BioMed Central, 2015, 5 (1), pp.25. ⟨10.1186/s13569-015-0040-0⟩. ⟨hal-03623738⟩
  • Adam Wolfe, Bisrat Debeb, Lara Lacerda, Richard Larson, Arvind Bambhroliya, et al.. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Research and Treatment, Springer Verlag, 2015, 154 (3), pp.495-508. ⟨10.1007/s10549-015-3645-3⟩. ⟨hal-03623740⟩
  • Axel Le Cesne, Isabelle Ray-Coquard, Florence Duffaud, Christine Chevreau, Nicolas Penel, et al.. Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group. European Journal of Cancer, Elsevier, 2015, 51 (6), pp.742-750. ⟨10.1016/j.ejca.2015.01.006⟩. ⟨hal-03623749⟩
  • Patricia Pautier, Anne Floquet, Christine Chevreau, Nicolas Penel, Cécile Guillemet, et al.. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncology, Elsevier, 2015, 16 (4), pp.457-464. ⟨10.1016/s1470-2045(15)70070-7⟩. ⟨hal-03623745⟩
  • Axel Le Cesne, Jean-yves Blay, Julien Domont, Emmanuelle Tresch-Bruneel, Christine Chevreau, et al.. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Lancet Oncology, Elsevier, 2015, 16 (3), pp.312-319. ⟨10.1016/s1470-2045(15)70031-8⟩. ⟨hal-03623747⟩
  • François Bertucci, Pascal Finetti, Cécile Colpaert, Emilie Mamessier, Maxime Parizel, et al.. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget, Impact journals, 2015, 6 (15), pp.13506-13519. ⟨10.18632/oncotarget.3642⟩. ⟨hal-03583483⟩
  • Andrea Remo, Ines Simeone, Massimo Pancione, Pietro Parcesepe, Pascal Finetti, et al.. Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer. Journal of Translational Medicine, BioMed Central, 2015, 13 (1), pp.138. ⟨10.1186/s12967-015-0492-2⟩. ⟨inserm-01264508⟩
  • A Laroche-Clary, V Chaire, V Le Morvan, A. Neuville, F. Bertucci, et al.. BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients. British Journal of Cancer, Cancer Research UK, 2015, 112 (4), pp.688-692. ⟨10.1038/bjc.2014.624⟩. ⟨hal-02277467⟩
  • François Bertucci, Pascal Finetti, Renaud Sabatier, Daniel Birnbaum. The CINSARC signature: Prognostic and predictive of response to chemotherapy?. Cell Cycle, Taylor & Francis, 2014, 9 (19), pp.4025-4027. ⟨10.4161/cc.9.19.13463⟩. ⟨hal-03623803⟩
  • Renaud Sabatier, Pascal Finetti, Arnaud Guille, José Adelaïde, Max Chaffanet, et al.. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. Molecular Cancer, BioMed Central, 2014, 13, pp.228. ⟨10.2174/156652412798376134⟩. ⟨inserm-01192813⟩
  • Emilie Mamessier, François Bertucci, Renaud Sabatier, Daniel Birnbaum, Daniel Olive. "Stealth" tumors: Breast cancer cells shun NK-cells anti-tumor immunity. OncoImmunology, Taylor & Francis, 2014, 1 (3), pp.366-368. ⟨10.4161/onci.18528⟩. ⟨hal-03583489⟩
  • Marina Vita, Julie C Tisserand, Isaure Chauvot de Beauchêne, Nicolas Panel, Luba Tchertanov, et al.. Characterization of S628N: a novel KIT mutation found in a metastatic melanoma. JAMA Dermatology, American Medical Association, 2014, 150 (12), ⟨10.1001/jamadermatol.2014.1437⟩. ⟨hal-01505849⟩
  • Audrey Monneur, François Bertucci, Patrice Viens, Anthony Gonçalves. Traitements systémiques des cancers du sein inflammatoires : un état des lieux. Bulletin du Cancer, John Libbey Eurotext, 2014, 101 (12), pp.1080-1088. ⟨10.1684/bdc.2014.2014⟩. ⟨hal-03623752⟩
  • Pascal Finetti, Arnaud Guille, José Adelaide, Daniel Birnbaum, Max Chaffanet, et al.. ESPL1 is a candidate oncogene of luminal B breast cancers. Breast Cancer Research and Treatment, Springer Verlag, 2014, 147 (1), pp.51-59. ⟨10.1007/s10549-014-3070-z⟩. ⟨hal-03623756⟩
  • Mandy Brecqueville, José Adélaïde, François Bertucci, Pascal Finetti, Max Chaffanet, et al.. Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms. Cell Cycle, Taylor & Francis, 2014, 11 (16), pp.3141-3142. ⟨10.4161/cc.21114⟩. ⟨hal-03623775⟩
  • François Bertucci, Pascal Finetti, Peter Vermeulen, Peter van Dam, Luc Dirix, et al.. Genomic profiling of inflammatory breast cancer: A review. Breast, Elsevier, 2014, 23 (5), pp.538-545. ⟨10.1016/j.breast.2014.06.008⟩. ⟨hal-03623757⟩
  • Maria Katsogiannou, Claudia Andrieu, Virginie Baylot, Anaïs Baudot, Nelson J Dusetti, et al.. The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets.. Molecular and Cellular Proteomics, American Society for Biochemistry and Molecular Biology, 2014, pp.3585-601. ⟨10.1074/mcp.M114.041228⟩. ⟨hal-01104661⟩
  • Rita El Helou, Julien Wicinski, Arnaud Guille, José Adelaïde, Pascal Finetti, et al.. Brief Reports: A Distinct DNA Methylation Signature Defines Breast Cancer Stem Cells and Predicts Cancer Outcome. STEM CELLS, AlphaMed Press, 2014, 32 (11), pp.3031-3036. ⟨10.1002/stem.1792⟩. ⟨hal-01431934⟩
  • Marine Gilabert, Simon Launay, Christophe Ginestier, François Bertucci, Stéphane Audebert, et al.. Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib. PLoS ONE, Public Library of Science, 2014, 9 (8), pp.e104302. ⟨10.1371/journal.pone.0104302⟩. ⟨hal-01431935⟩
  • François Bertucci, Pascal Finetti, Patrice Viens, Daniel Birnbaum. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. Cancer Letters, Elsevier, 2014, 355 (1), pp.70-75. ⟨10.1016/j.canlet.2014.09.014⟩. ⟨hal-03623754⟩
  • Joséphine Zangari, Mariagrazia Partisani, François Bertucci, Julie Milanini, Ghislain Bidaut, et al.. EFA6B Antagonizes Breast Cancer. Cancer Research, American Association for Cancer Research, 2014, 74 (19), pp.5493-5506. ⟨10.1158/0008-5472.can-14-0298⟩. ⟨hal-03623755⟩
  • Renaud Sabatier, Anthony Gonçalves, François Bertucci. Personalized medicine: Present and future of breast cancer management. Critical Reviews in Oncology/Hematology, Elsevier, 2014, 91 (3), pp.223-233. ⟨10.1016/j.critrevonc.2014.03.002⟩. ⟨hal-03623758⟩
  • Laurys Boudin, Nicolas Fakhry, Bruno Chetaille, Delphine Perrot, Anh Tuan Nguyen, et al.. Primary Synovial Sarcoma of the Thyroid Gland: Case Report and Review of the Literature. Case Reports in Oncology, Basel : Karger, 2014, 7 (1), pp.6-13. ⟨10.1159/000357913⟩. ⟨hal-03623760⟩
  • Stéphanie Cornen, Arnaud Guille, José Adelaïde, Lynda Addou-Klouche, Pascal Finetti, et al.. Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling. PLoS ONE, Public Library of Science, 2014, 9 (1), pp.e81843. ⟨10.1371/journal.pone.0081843⟩. ⟨hal-01614950⟩
  • Lauriane Eberst, Claire Cropet, Axel Le Cesne, Patricia Pautier, Nicolas Penel, et al.. The off-label use of targeted therapies in sarcomas: the OUTC’S program. BMC Cancer, BioMed Central, 2014, 14 (1), pp.870. ⟨10.1186/1471-2407-14-870⟩. ⟨hal-03623753⟩
  • François Bertucci, Pascal Finetti, Patrice Viens, Daniel Birnbaum. Difference in Therapeutic Response Between Basal and Nonbasal Triple-Negative Breast Cancers. Oncologist, AlphaMed Press, 2013, 18 (9), pp.1060-1061. ⟨10.1634/theoncologist.2013-0121⟩. ⟨hal-03623765⟩
  • Jean-yves Blay, Antoine Italiano, Isabelle Ray-Coquard, Axel Le Cesne, Florence Duffaud, et al.. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer, BioMed Central, 2013, 13 (1), pp.64. ⟨10.1186/1471-2407-13-64⟩. ⟨hal-03623768⟩
  • V. Gelsi-Boyer, N. Cervera, François Bertucci, M. Brecqueville, P. Finetti, et al.. Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. Haematologica, Ferrata Storti Foundation, 2013, 98 (4), pp.576-583. ⟨10.3324/haematol.2012.071506⟩. ⟨hal-03623773⟩
  • Marion A. Salvador, Julien Wicinski, Olivier Cabaud, yves Toiron, Pascal Finetti, et al.. The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression. Clinical Cancer Research, American Association for Cancer Research, 2013, 19 (23), pp.6520-6531. ⟨10.1158/1078-0432.CCR-13-0877⟩. ⟨hal-01431936⟩
  • Corinne Bouvier, François Bertucci, Philippe Métellus, Pascal Finetti, André Maues de Paula, et al.. ALDH1 is an immunohistochemical diagnostic marker for solitary fibrous tumours and haemangiopericytomas of the meninges emerging from gene profiling study. Acta Neuropathologica Communications, BioMed Central part of Springer Science, 2013, 1 (1), pp.10. ⟨inserm-00837790⟩
  • François Bertucci, Corinne Bouvier‐labit, Pascal Finetti, José Adélaïde, Philippe Metellus, et al.. Comprehensive genome characterization of solitary fibrous tumors using high‐resolution array‐based comparative genomic hybridization. Genes, Chromosomes and Cancer, Wiley, 2013, 52 (2), pp.156-164. ⟨10.1002/gcc.22015⟩. ⟨hal-03623772⟩
  • Anthony Gonçalves, Jessica Moretta, François Eisinger, François Bertucci. Médecine personnalisée et cancer du sein : médecine anticipatoire, évaluation pronostique et ciblage thérapeutique. Bulletin du Cancer, John Libbey Eurotext, 2013, 100 (12), pp.1295-1310. ⟨10.1684/bdc.2013.1856⟩. ⟨hal-03623762⟩
  • Emmanuelle Charafe-Jauffret, Christophe Ginestier, François Bertucci, Olivier Cabaud, Julien Wicinski, et al.. ALDH1-Positive Cancer Stem Cells Predict Engraftment of Primary Breast Tumors and Are Governed by a Common Stem Cell Program. Cancer Research, American Association for Cancer Research, 2013, 73 (24), pp.7290-7300. ⟨10.1158/0008-5472.CAN-12-4704⟩. ⟨hal-01431937⟩
  • Laurence Moureau-Zabotto, Olivier Turrini, Michel Resbeut, Jean-Luc Raoul, Marc Giovannini, et al.. Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma. BMC Cancer, BioMed Central, 2013, 13 (1), pp.568. ⟨10.1186/1471-2407-13-568⟩. ⟨hal-03623761⟩
  • Anthony Gonçalves, Renaud Sabatier, Emmanuelle Charafe-Jauffret, Marine Gilabert, Magali Provansal, et al.. Cancer du sein triple-négatif : caractéristiques histocliniques et moléculaires, prise en charge et perspectives thérapeutiques. Bulletin du Cancer, John Libbey Eurotext, 2013, 100 (5), pp.453-464. ⟨10.1684/bdc.2013.1740⟩. ⟨hal-03623766⟩
  • Wendy Woodward, Savitri Krishnamurthy, Hideko yamauchi, Randa El-Zein, Dai Ogura, et al.. Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Research and Treatment, Springer Verlag, 2013, 138 (3), pp.761-772. ⟨10.1007/s10549-013-2501-6⟩. ⟨hal-03623767⟩
  • Steven van Laere, Naoto Ueno, Pascal Finetti, Peter Vermeulen, Anthony Lucci, et al.. Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. Clinical Cancer Research, American Association for Cancer Research, 2013, 19 (17), pp.4685-4696. ⟨10.1158/1078-0432.ccr-12-2549⟩. ⟨hal-03623770⟩
  • Audrey Monneur, Bruno Chetaille, Delphine Perrot, Jérôme Guiramand, François Bertucci. Dramatic and Delayed Response to Doxorubicin-Dacarbazine Chemotherapy of a Giant Desmoid Tumor: Case Report and Literature Review. Case Reports in Oncology, Basel : Karger, 2013, 6 (1), pp.127-133. ⟨10.1159/000349918⟩. ⟨hal-03623771⟩
  • Emilie Mamessier, C. Pradel, M.-L. Thibult, C. Drevet, A. Zouine, et al.. Peripheral Blood NK Cells from Breast Cancer Patients Are Tumor-Induced Composite Subsets. Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2013, 190 (5), pp.2424 - 2436. ⟨10.4049/jimmunol.1200140⟩. ⟨hal-01765648⟩
  • Fredika Robertson, Emanuel Petricoin Iii, Steven van Laere, François Bertucci, Khoi Chu, et al.. Presence of anaplastic lymphoma kinase in inflammatory breast cancer. SpringerPlus, SpringerOpen, 2013, 2 (1), pp.497. ⟨10.1186/2193-1801-2-497⟩. ⟨hal-03623764⟩
  • Hiroko Masuda, Keith Baggerly, ying Wang, Takayuki Iwamoto, Takae Brewer, et al.. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Research, BioMed Central, 2013, 15 (6), pp.R112. ⟨10.1186/bcr3579⟩. ⟨hal-03623763⟩
  • François Bertucci, Corinne Bouvier-Labit, Pascal Finetti, Philippe Metellus, José Adelaïde, et al.. Gene Expression Profiling of Solitary Fibrous Tumors. PLoS ONE, Public Library of Science, 2013, 8 (5), pp.e64497. ⟨10.1371/journal.pone.0064497⟩. ⟨hal-01537869⟩
  • E. Mamessier, Lydie Pradel, M.-L. Thibult, C. Drevet, A. Zouine, et al.. Peripheral Blood NK Cells from Breast Cancer Patients Are Tumor-Induced Composite Subsets. Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2013, 190 (5), pp.2424--2436. ⟨10.4049/jimmunol.1200140⟩. ⟨hal-01612099⟩
  • Jocelyne Jacquemier, François Bertucci, Pascal Finetti, Benjamin Esterni, Emmanuelle Charafe-Jauffret, et al.. High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. International Journal of Cancer, Wiley, 2012, 130 (1), pp.96-104. ⟨10.1002/ijc.25979⟩. ⟨hal-03623783⟩
  • Laura Beyer, Jean-Robert Delpero, Bruno Chetaille, Anthony Sarran, Delphine Perrot, et al.. Solitary Fibrous Tumor in the Round Ligament of the Liver: A Fortunate Intraoperative Discovery. Case Reports in Oncology, Basel : Karger, 2012, 5 (1), pp.187-194. ⟨10.1159/000338616⟩. ⟨hal-03623784⟩
  • Laurence Moureau-Zabotto, Bruno Chetaille, Franck Bladou, Pierre-yves Dauvergne, Myriam Marcy, et al.. Solitary Fibrous Tumor of the Prostate: Case Report and Review of the Literature. Case Reports in Oncology, Basel : Karger, 2012, 5 (1), pp.22-29. ⟨10.1159/000335680⟩. ⟨hal-03623785⟩
  • Antoine Italiano, Angela Cioffi, Nicolas Penel, Matteo Giaj Levra, Corinne Delcambre, et al.. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer, Wiley, 2012, 118 (13), pp.3330-3336. ⟨10.1002/cncr.26599⟩. ⟨hal-03623788⟩
  • J. Gillibert-Duplantier, B. Duthey, V. Sisirak, D. Salaün, T. Gargi, et al.. Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis.. Oncogene, Nature Publishing Group, 2012, 31 (30), pp.3516-24. ⟨10.1038/onc.2011.525⟩. ⟨hal-00820060⟩
  • François Bertucci, Julia Araujo, Marc Giovannini. Pancreatic metastasis from osteosarcoma and Ewing sarcoma: literature review. Scandinavian Journal of Gastroenterology, Taylor & Francis, 2012, 48 (1), pp.4-8. ⟨10.3109/00365521.2012.711852⟩. ⟨hal-03623774⟩
  • Mandy Brecqueville, Jérôme Rey, François Bertucci, Emilie Coppin, Pascal Finetti, et al.. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes, Chromosomes and Cancer, Wiley, 2012, 51 (8), pp.743-755. ⟨10.1002/gcc.21960⟩. ⟨hal-03623779⟩
  • Gais Kadra, Pascal Finetti, yves Toiron, Patrice Viens, Daniel Birnbaum, et al.. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. Breast Cancer Research and Treatment, Springer Verlag, 2012, 132 (3), pp.1035-1047. ⟨10.1007/s10549-011-1687-8⟩. ⟨hal-03623793⟩
  • Michael Guedj, Laëtitia Marisa, Aurélien de Reynies, Béatrice Orsetti, Renaud Schiappa, et al.. A refined molecular taxonomy of breast cancer.: molecular classification of breast cancer. Oncogene, Nature Publishing Group, 2012, 31 (9), pp.1196-206. ⟨10.1038/onc.2011.301⟩. ⟨inserm-00611752⟩
  • Renaud Sabatier, Anthony Gonçalves, François Bertucci, Maria-Antonietta Capiello, Frédérique Rousseau, et al.. Are there candidates for high-dose chemotherapy in ovarian carcinoma?. Journal of Experimental and Clinical Cancer Research, BioMed Central, 2012, 31 (1), pp.87. ⟨10.1186/1756-9966-31-87⟩. ⟨inserm-00765646⟩
  • François Bertucci, Arnaud Lagarde, Anthony Ferrari, Pascal Finetti, Emmanuelle Charafe-Jauffret, et al.. 8q24 Cancer Risk Allele Associated with Major Metastatic Risk in Inflammatory Breast Cancer. PLoS ONE, Public Library of Science, 2012, 7 (5), pp.e37943. ⟨10.1371/journal.pone.0037943⟩. ⟨hal-03623777⟩
  • Christophe Ginestier, Florence Monville, Julien Wicinski, Olivier Cabaud, Nathalie Cervera, et al.. Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target. STEM CELLS, AlphaMed Press, 2012, 30 (7), pp.1327-1337. ⟨10.1002/stem.1122⟩. ⟨hal-01431941⟩
  • Juliette Thariat, René-Jean Bensadoun, Marie-Christine Etienne-Grimaldi, Dominique Grall, Frédérique Penault-Llorca, et al.. Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02).. Clinical Cancer Research, American Association for Cancer Research, 2012, 18 (18), pp.5123-33. ⟨10.1158/1078-0432.CCR-12-1518⟩. ⟨hal-00770510⟩
  • Renaud Sabatier, Céline Roussin, Jean-Pierre Riviere, Aurélie Jalaguier, Jocelyne Jacquemier, et al.. Breast Metastasis of a Squamous Cell Carcinoma of the Uterine Cervix Mimicking Inflammatory Breast Cancer. Case Reports in Oncology, Basel : Karger, 2012, 5 (2), pp.464-470. ⟨10.1159/000342255⟩. ⟨hal-03623778⟩
  • Isabelle Pellegrini, Myrto Rapti, Jean-Marc Extra, Anouk Petri-Cal, Themis Apostolidis, et al.. Chimiothérapie ciblée du cancer du sein basée sur une analyse génomique de la tumeur. médecine/sciences, EDP Sciences, 2012, 28, pp.24-27. ⟨10.1051/medsci/2012281s107⟩. ⟨hal-03623782⟩
  • François Bertucci, Daniel Birnbaum. Génomique et recherche clinique en cancérologie mammaire. médecine/sciences, EDP Sciences, 2012, 28, pp.14-18. ⟨10.1051/medsci/2012281s105⟩. ⟨hal-03623780⟩
  • Patricia Marino, François Bertucci, Anthony Gonçalves, Valérie Seror. Tests diagnostiques et thérapies ciblées en cancérologie. médecine/sciences, EDP Sciences, 2012, 28, pp.19-23. ⟨10.1051/medsci/2012281s106⟩. ⟨hal-03623781⟩
  • Philippe Cassier, Elena Fumagalli, Piotr Rutkowski, Patrick Schöffski, Martine van Glabbeke, et al.. Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. Clinical Cancer Research, American Association for Cancer Research, 2012, 18 (16), pp.4458-4464. ⟨10.1158/1078-0432.ccr-11-3025⟩. ⟨hal-03623776⟩
  • Antoine Adenis, Olivier Bouché, François Bertucci, Elsa Kalbacher, Charles Fournier, et al.. Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors.. Medical oncology and tumor pharmacotherapy, Springer-Verlag;Humana Press, 2012, 29 (4), pp.3003-8. ⟨10.1007/s12032-012-0204-1⟩. ⟨hal-00850693⟩
  • Maxime Garcia, Raphaelle Millat-Carus, François Bertucci, Pascal Finetti, Daniel Birnbaum, et al.. Interactome-Transcriptome integration for predicting distant metastasis in breast cancer. Bioinformatics, Oxford University Press (OUP), 2012, 28 (5), pp.672-678. ⟨10.1093/bioinformatics/bts025⟩. ⟨hal-01784470⟩
  • Ismahane Bekhouche, Pascal Finetti, José Adelaïde, Anthony Ferrari, Carole Tarpin, et al.. High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes. PLoS ONE, Public Library of Science, 2011, 6 (2), pp.e16950. ⟨10.1371/journal.pone.0016950⟩. ⟨hal-03623798⟩
  • François Bertucci, Bruno Chetaille, Luc Xerri. Gene Expression Profiling for In Silico Microdissection of Hodgkin's Lymphoma Microenvironment and Identification of Prognostic Features. Advances in Hematology, Hindawi, 2011, 2011, pp.1-8. ⟨10.1155/2011/485310⟩. ⟨hal-03623801⟩
  • Emilie Mamessier, A. Sylvain, F. Bertucci, R. Castellano, P. Finetti, et al.. Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition. Cancer Research, American Association for Cancer Research, 2011, 71 (21), pp.6621 - 6632. ⟨10.1158/0008-5472.CAN-11-0792⟩. ⟨hal-01765652⟩
  • Emilie Mamessier, Aude Sylvain, Marie-Laure Thibult, Gilles Houvenaeghel, Jocelyne Jacquemier, et al.. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. Journal of Clinical Investigation, American Society for Clinical Investigation, 2011, 121 (9), pp.3609 - 3622. ⟨10.1172/JCI45816⟩. ⟨hal-01765654⟩
  • Renaud Sabatier, Pascal Finetti, Emilie Mamessier, Stéphane Raynaud, Nathalie Cervera, et al.. Kinome expression profiling and prognosis of basal breast cancers. Molecular Cancer, BioMed Central, 2011, 10 (1), pp.86. ⟨10.1186/1476-4598-10-86⟩. ⟨hal-03606422⟩
  • Salvatore Spicuglia, Christelle Vincent-Fabert, Touati Benoukraf, Guillaume Tibéri, Andrew J Saurin, et al.. Characterisation of Genome-Wide PLZF/RARA Target Genes. PLoS ONE, Public Library of Science, 2011, 6 (9), pp.e24176. ⟨10.1371/journal.pone.0024176⟩. ⟨hal-00674513⟩
  • François Bertucci. Endometriosis-Associated Ovarian Carcinomas. New England Journal of Medicine, Massachusetts Medical Society, 2011, 364 (5), pp.482-485. ⟨10.1056/nejmc1012780⟩. ⟨hal-03623797⟩
  • Renaud Sabatier, Pascal Finetti, José Adelaide, Arnaud Guille, Jean-Paul Borg, et al.. Down-Regulation of ECRG4, a Candidate Tumor Suppressor Gene, in Human Breast Cancer. PLoS ONE, Public Library of Science, 2011, 6 (11), pp.e27656. ⟨10.1371/journal.pone.0027656⟩. ⟨hal-03623789⟩
  • Anthony Gonçalves, Patrice Viens, Marine Gilabert, Olivier Turrini, Éric Lambaudie, et al.. Planification systématique de l'apprentissage hospitalier de la cancérologie par les étudiants en DCEM. Bulletin du Cancer, John Libbey Eurotext, 2011, 98 (12), pp.1489-1508. ⟨10.1684/bdc.2011.1504⟩. ⟨hal-03623787⟩
  • Xi Wen Zhao, Ellen van Beek, Karin Schornagel, Hans van Der Maaden, Michel van Houdt, et al.. CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proceedings of the National Academy of Sciences of the United States of America, National Academy of Sciences, 2011, 108 (45), pp.18342-18347. ⟨10.1073/pnas.1106550108⟩. ⟨hal-03623790⟩
  • Simon Launay, Bruno Chetaille, Fanny Medina, Delphine Perrot, Serge Nazarian, et al.. Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review. BMC Cancer, BioMed Central, 2011, 11 (1), pp.423. ⟨10.1186/1471-2407-11-423⟩. ⟨hal-03623791⟩
  • Renaud Sabatier, Jocelyne Jacquemier, François Bertucci, Benjamin Esterni, Pascal Finetti, et al.. Peritumoural vascular invasion: A major determinant of triple-negative breast cancer outcome. European Journal of Cancer, Elsevier, 2011, 47 (10), pp.1537-1545. ⟨10.1016/j.ejca.2011.02.002⟩. ⟨hal-03623796⟩
  • Anthony Goncalves, François Bertucci. Clinical Application of Proteomics in Breast Cancer: State of the Art and Perspectives. Medical Principles and Practice, Karger, 2011, 20 (1), pp.4-18. ⟨10.1159/000319544⟩. ⟨hal-03623800⟩
  • Fabrice Sircoulomb, Nathalie Nicolas, Anthony Ferrari, Pascal Finetti, Ismahane Bekhouche, et al.. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Molecular Medicine, Wiley Open Access, 2011, 3 (3), pp.153-166. ⟨10.1002/emmm.201100121⟩. ⟨hal-01431945⟩
  • Jocelyne Jacquemier, Jean-Marie Boher, Henri Roche, Benjamin Esterni, Daniel Serin, et al.. Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial.. Breast Cancer Research, BioMed Central, 2011, 13 (6), pp.R109. ⟨10.1186/bcr3051⟩. ⟨inserm-00647247⟩
  • Aurore Blesius, Philippe A Cassier, François Bertucci, Jérome Fayette, Isabelle Ray-Coquard, et al.. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.. BMC Cancer, BioMed Central, 2011, 11, pp.72. ⟨10.1186/1471-2407-11-72⟩. ⟨hal-00779604⟩
  • Renaud Sabatier, Pascal Finetti, Emilie Mamessier, Stéphane Raynaud, Nathalie Cervera, et al.. Kinome expression profiling and prognosis of basal breast cancers.. Molecular Cancer, BioMed Central, 2011, 10 (1), pp.86. ⟨10.1186/1476-4598-10-86⟩. ⟨inserm-00614833⟩
  • Cécile Cauvin, Laurence Moureau-Zabotto, Bruno Chetaille, Werner Hilgers, yves Denoux, et al.. Primary leiomyosarcoma of the seminal vesicle: Case report and review of the literature. BMC Cancer, BioMed Central, 2011, 11 (1), pp.323. ⟨10.1186/1471-2407-11-323⟩. ⟨hal-03623794⟩
  • Pierre Ambrosi, François Bertucci, Bernard Kreitmann. High incidence of asymptomatic renal cancer in late survivors after heart transplantation. The Journal of Heart and Lung Transplantation, Elsevier, 2011, 30 (10), pp.1202-1203. ⟨10.1016/j.healun.2011.05.003⟩. ⟨hal-03623795⟩
  • ying yang, Sébastien Létard, Laurence Borge, Amandine Chaix, Katia Hanssens, et al.. Pediatric mastocytosis–associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood, American Society of Hematology, 2010, 116 (7), pp.1114-1123. ⟨10.1182/blood-2009-06-226027⟩. ⟨hal-03623808⟩
  • Renaud Sabatier, José Adélaïde, Pascal Finetti, Anthony Ferrari, Laetitia Huiart, et al.. BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer. Genes, Chromosomes and Cancer, Wiley, 2010, 49 (12), pp.1143-1151. ⟨10.1002/gcc.20822⟩. ⟨hal-03623799⟩
  • Fabrice Sircoulomb, Ismahane Bekhouche, Pascal Finetti, José Adélaïde, Azza Ben Hamida, et al.. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer, BioMed Central, 2010, 10 (1), pp.539. ⟨10.1186/1471-2407-10-539⟩. ⟨hal-03623802⟩
  • M. Humbert, N. Casteran, S. Letard, K. Hanssens, J. Iovanna, et al.. Masitinib combined with standard Gemcitabine chemotherapy : in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS ONE, Public Library of Science, 2010, 5 (3), pp.e9430-e9437. ⟨10.1371/journal.pone.0009430⟩. ⟨hal-00473110⟩
  • Renaud Sabatier, Corinne Bouvier, Gonzague de Pinieux, Anthony Sarran, Isabelle Brenot-Rossi, et al.. Low-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature.. BMC Cancer, BioMed Central, 2010, 10, pp.645. ⟨10.1186/1471-2407-10-645⟩. ⟨hal-00546735⟩
  • Patricia Marino, Carole Siani, François Bertucci, Henri Roche, Anne-Laure Martin, et al.. Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients. Breast Cancer Research and Treatment, Springer Verlag, 2010, 129 (2), pp.401-409. ⟨10.1007/s10549-010-1242-z⟩. ⟨hal-00615386⟩
  • Axel Le Cesne, Isabelle Ray-Coquard, Binh Nguyen Bui, Antoine Adenis, Maria Rios, et al.. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncology, Elsevier, 2010, 11 (10), pp.942-949. ⟨10.1016/s1470-2045(10)70222-9⟩. ⟨hal-03623804⟩
  • Marine Gilabert, Stéphane Audebert, Patrice Viens, Jean-Paul Borg, François Bertucci, et al.. Protéomique et cancer du sein : à la recherche de nouveaux biomarqueurs diagnostiques et théragnostiques. Bulletin du Cancer, John Libbey Eurotext, 2010, 97 (3), pp.321-339. ⟨10.1684/bdc.2010.1061⟩. ⟨hal-03623810⟩
  • Hugues de Lavallade, Pascal Finetti, Nadine Carbuccia, Jamshid Khorashad, Aude Charbonnier, et al.. A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leukemia Research, Elsevier, 2010, 34 (2), pp.254-257. ⟨10.1016/j.leukres.2009.09.026⟩. ⟨hal-03623812⟩
  • Lynda Addou-Klouche, José Adélaïde, Pascal Finetti, Nathalie Cervera, Anthony Ferrari, et al.. Loss, mutation and deregulation of L3MBTL4 in breast cancers. Molecular Cancer, BioMed Central, 2010, 9 (1), pp.213. ⟨10.1186/1476-4598-9-213⟩. ⟨hal-03623805⟩
  • François Bertucci, Nathalie Borie, Henri Roche, Thomas Bachelot, Jean-Marc Doussal, et al.. Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Research and Treatment, Springer Verlag, 2010, 127 (2), pp.363-373. ⟨10.1007/s10549-010-1003-z⟩. ⟨hal-00594464⟩
  • Anthony Gonçalves, Pascal Finetti, Renaud Sabatier, Marine Gilabert, José Adelaïde, et al.. -- mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Research and Treatment, Springer Verlag, 2010, 127 (1), pp.273-281. ⟨10.1007/s10549-010-1199-y⟩. ⟨hal-00594471⟩
  • Renaud Sabatier, Pascal Finetti, Nathalie Cervera, Eric Lambaudie, Benjamin Esterni, et al.. A gene expression signature identifies two prognostic subgroups of basal breast cancer: Multigene prognostic classification of basal breast cancers. Breast Cancer Research and Treatment, Springer Verlag, 2010, 126 (2), pp.407-420. ⟨10.1007/s10549-010-0897-9⟩. ⟨hal-00583558⟩
  • Emmanuelle Charafe-Jauffret, Christophe Ginestier, Flora Iovino, Carole Tarpin, Mark Diebel, et al.. Aldehyde Dehydrogenase 1-Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer. Clinical Cancer Research, American Association for Cancer Research, 2010, 16 (1), pp.45-55. ⟨10.1158/1078-0432.CCR-09-1630⟩. ⟨hal-01431949⟩
  • Patrice Viens, Carole Tarpin, Henri Roche, François Bertucci. Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies. Cancer, Wiley, 2010, 116 (S11), pp.2829-2836. ⟨10.1002/cncr.25168⟩. ⟨hal-03623807⟩
  • Emilie Romeo, Olivier Gisserot, Jean-Pierre de Jaureguiberry, Nicolas Desse, Jean-Baptiste Souraud, et al.. Meningeal chondroblastic osteosarcoma: case report and review of the literature. Journal of Neuro-Oncology, Springer Verlag, 2010, 100 (2), pp.305-309. ⟨10.1007/s11060-010-0167-z⟩. ⟨hal-03623809⟩
  • David Birnbaum, Renaud Sabatier, Emilie Mamessier, Daniel Birnbaum, François Bertucci. Une forme « ariditaire » du cancer de l’ovaire. médecine/sciences, EDP Sciences, 2010, 26 (12), pp.1040-1042. ⟨10.1051/medsci/201026121040⟩. ⟨hal-03583491⟩
  • François Bertucci, Pascal Finetti, Daniel Birnbaum, Patrice Viens. Gene expression profiling of inflammatory breast cancer. Cancer, Wiley, 2010, 116 (S11), pp.2783-2793. ⟨10.1002/cncr.25165⟩. ⟨hal-03623806⟩
  • Bruno Chetaille, François Bertucci, Pascal Finetti, Benjamin Esterni, Aspasia Stamatoullas, et al.. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood, American Society of Hematology, 2009, 113 (12), pp.2765-3775. ⟨10.1182/blood-2008-07-168096⟩. ⟨hal-03623820⟩
  • Emmanuelle Charafe-Jauffret, Christophe Ginestier, Flora Iovino, Julien Wicinski, Nathalie Cervera, et al.. Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature. Cancer Research, American Association for Cancer Research, 2009, 69 (4), pp.1302-1313. ⟨10.1158/0008-5472.CAN-08-2741⟩. ⟨hal-01431954⟩
  • Anthony Gonçalves, Mathilde Deblock, Benjamin Esterni, Carole Tarpin, François Bertucci, et al.. Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status. Anti-Cancer Drugs, Lippincott, Williams & Wilkins, 2009, 20 (10), pp.946-952. ⟨10.1097/cad.0b013e328331178f⟩. ⟨hal-03623811⟩
  • An-Ting Lu, Shelley Salpeter, Anthony Reeve, Steven Eschrich, Patrick Johnston, et al.. Gene Expression Profiles as Predictors of Poor Outcomes in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis. Clinical Colorectal Cancer, Elsevier, 2009, 8 (4), pp.207-214. ⟨10.3816/ccc.2009.n.035⟩. ⟨hal-03623813⟩
  • Jocelyne Jacquemier, Emmanuelle Charafe-Jauffret, Florence Monville, Benjamin Esterni, Jean Marc Extra, et al.. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Research, BioMed Central, 2009, 11 (2), pp.R23. ⟨10.1186/bcr2249⟩. ⟨hal-03623814⟩
  • François Bertucci, Daniel Birnbaum. Distant metastasis: not out of reach any more. Journal of Biology, BioMed Central, 2009, 8 (3), pp.28. ⟨10.1186/jbiol128⟩. ⟨hal-03623815⟩
  • Renaud Sabatier, Pascal Finetti, Nathalie Cervera, Daniel Birnbaum, François Bertucci. Gene expression profiling and prediction of clinical outcome in ovarian cancer. Critical Reviews in Oncology/Hematology, Elsevier, 2009, 72 (2), pp.98-109. ⟨10.1016/j.critrevonc.2009.01.007⟩. ⟨hal-03623817⟩
  • Gwladys Zabouo, Anne-Marie Imbert, Jocelyne Jacquemier, Pascal Finetti, Thomas Moreau, et al.. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Research, BioMed Central, 2009, 11 (1), pp.R1. ⟨10.1186/bcr2215⟩. ⟨hal-03623818⟩
  • Christophe Ginestier, Julien Wicinski, Nathalie Cervera, Florence Monville, Pascal Finetti, et al.. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle, Taylor & Francis, 2009, 8 (20), pp.3297-3302. ⟨10.4161/cc.8.20.9761⟩. ⟨hal-01431955⟩
  • François Bertucci, Pascal Finetti, Nathalie Cervera, Emmanuelle Charafe-Jauffret, Max Buttarelli, et al.. How different are luminal A and basal breast cancers?. International Journal of Cancer, Wiley, 2009, 124 (6), pp.1338-1348. ⟨10.1002/ijc.24055⟩. ⟨hal-03623816⟩
  • François Bertucci, Daniel Birnbaum. Reasons for breast cancer heterogeneity. Journal of Biology, BioMed Central, 2008, 7 (2), pp.6. ⟨10.1186/jbiol67⟩. ⟨hal-03623828⟩
  • F. Bertucci, Pascal Finetti, Nathalie Cervera, Benjamin Esterni, Fabienne Hermitte, et al.. How basal are triple-negative breast cancers?. International Journal of Cancer, Wiley, 2008, 123 (1), pp.236-240. ⟨10.1002/ijc.23518⟩. ⟨hal-03623624⟩
  • Emanuelle Charafe-Jauffret, Christophe Ginestier, Florence Monville, Julien Wicinski, François Bertucci, et al.. Stem cells and epithelial cancers: the example of breast cancer. Annales de Pathologie, Elsevier Masson, 2008, 28, pp.S30-S32. ⟨10.1016/j.annpat.2008.09.005⟩. ⟨hal-01431960⟩
  • François Bertucci, Béatrice Orsetti, Vincent Nègre, Pascal Finetti, Carole Rougé, et al.. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles.. Oncogene, Nature Publishing Group, 2008, 27 (40), pp.5359-72. ⟨10.1038/onc.2008.158⟩. ⟨inserm-00290484⟩
  • Anthony Gonçalves, Séverine Esteyries, Brynn Taylor-Smedra, Arnaud Lagarde, Mounay Ayadi, et al.. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer, BioMed Central, 2008, 8 (1), pp.169. ⟨10.1186/1471-2407-8-169⟩. ⟨hal-03623821⟩
  • Anthony Goncçalves, Emmanuelle Charafe-Jauffret, François Bertucci, Stéphane Audebert, yves Toiron, et al.. Protein Profiling of Human Breast Tumor Cells Identifies Novel Biomarkers Associated with Molecular Subtypes. Molecular and Cellular Proteomics, 2008, 7 (8), pp.1420-1433. ⟨10.1074/mcp.m700487-mcp200⟩. ⟨hal-03623824⟩
  • Emmanuelle Charafe-Jauffret, Carole Tarpin, Patrice Viens, François Bertucci. Defining the Molecular Biology of Inflammatory Breast Cancer. Seminars in Oncology, WB Saunders, 2008, 35 (1), pp.41-50. ⟨10.1053/j.seminoncol.2007.11.015⟩. ⟨hal-03623825⟩
  • Pascal Finetti, Nathalie Cervera, Emmanuelle Charafe-Jauffret, Christian Chabannon, Colette Charpin, et al.. Sixteen–Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis. Cancer Research, American Association for Cancer Research, 2008, 68 (3), pp.767-776. ⟨10.1158/0008-5472.can-07-5516⟩. ⟨hal-03623826⟩
  • François Bertucci, Anthony Goncalves. Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery. Future Oncology, Future Medicine, 2008, 4 (2), pp.271-287. ⟨10.2217/14796694.4.2.271⟩. ⟨hal-03623823⟩
  • José Adélaïde, Pascal Finetti, Emmanuelle Charafe-Jauffret, Julien Wicinski, Jocelyne Jacquemier, et al.. Absence of ESR1 amplification in a series of breast cancers. International Journal of Cancer, Wiley, 2008, 123 (12), pp.2970-2972. ⟨10.1002/ijc.23786⟩. ⟨hal-03623819⟩
  • François Bertucci, Pascal Finetti, Nathalie Cervera, Daniel Birnbaum. Classification pronostique du cancer du sein et profils d’expression génique sur puces à ADN. médecine/sciences, EDP Sciences, 2008, 24 (6-7), pp.599-606. ⟨10.1051/medsci/20082467599⟩. ⟨hal-03623822⟩
  • Azza Ben Hamida, Intidhar Labidi, Karima Mrad, Emmanuelle Charafe-Jauffret, Saïda Ben Arab, et al.. Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin. BMC Cancer, BioMed Central, 2008, 8 (1), pp.28. ⟨10.1186/1471-2407-8-28⟩. ⟨hal-03623827⟩
  • François Bertucci, Daniel Birnbaum. Breast cancer genomics: real-time use. Lancet Oncology, Elsevier, 2007, 8 (12), pp.1045-1047. ⟨10.1016/s1470-2045(07)70350-9⟩. ⟨hal-03623829⟩
  • J. Adelaide, P. Finetti, I. Bekhouche, L. Repellini, J. Geneix, et al.. Integrated Profiling of Basal and Luminal Breast Cancers. Cancer Research, American Association for Cancer Research, 2007, 67 (24), pp.11565-11575. ⟨10.1158/0008-5472.can-07-2536⟩. ⟨hal-03623830⟩
  • François Bertucci. A Gene Signature in Breast Cancer. New England Journal of Medicine, Massachusetts Medical Society, 2007, 356 (18), pp.1887-1888. ⟨10.1056/nejmc070393⟩. ⟨hal-03623833⟩
  • C. Ginestier, J. Adelaiede, A. Goncalves, L. Repellini, F. Sircoulomb, et al.. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene, Nature Publishing Group, 2007, 26 (50), pp.7163-7169. ⟨10.1038/sj.onc.1210528⟩. ⟨hal-01431967⟩
  • Emmanuelle Charafe-Jauffret, Florence Monville, Francois Bertucci', Benjamin Esterni, Christophe Ginestier, et al.. Moesin expression is a marker of basal breast carcinomas. International Journal of Cancer, Wiley, 2007, 121 (8), pp.1779-1785. ⟨10.1002/ijc.22923⟩. ⟨hal-01431969⟩
  • Anne Madroszyk-Flandin, Sophie Bagattini, Anthony Gonçalves, Naji Salem, Frédéric Viret, et al.. Lung cancer in elderly patients: A retrospective analysis of practice in a single institution. Critical Reviews in Oncology/Hematology, Elsevier, 2007, 64 (1), pp.43-48. ⟨10.1016/j.critrevonc.2007.06.009⟩. ⟨hal-03623831⟩
  • François Bertucci, Anthony Gonçalves, Patrice Viens, Genevieve Monges, Patrice Dubreuil. Desmoid-Type Fibromatosis. Journal of Neurosurgery, American Association of Neurological Surgeons, 2007, 107 (2), pp.473-475. ⟨10.3171/jns-07/08/0473⟩. ⟨hal-03623832⟩
  • Emmanuelle Charafe-Jauffret, Max Chaffanet, François Bertucci, Christophe Ginestier, Jocelyne Jacquemier, et al.. Towards an integrated cellular and molecular: definition of breast cancers. médecine/sciences, EDP Sciences, 2007, 23 (6-7), pp.626-632. ⟨10.1051/medsci/20072367626⟩. ⟨hal-01431964⟩
  • François Bertucci, Daniel Birnbaum, Anthony Goncalves. Proteomics of Breast Cancer. Molecular and Cellular Proteomics, 2006, 5 (10), pp.1772-1786. ⟨10.1074/mcp.r600011-mcp200⟩. ⟨hal-03623834⟩
  • Christophe Ginestier, Nathalie Cervera, Pascal Finetti, Sverine Esteyries, Benjamin Esterni, et al.. Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clinical Cancer Research, American Association for Cancer Research, 2006, 12 (15), pp.4533-4544. ⟨10.1158/1078-0432.CCR-05-2339⟩. ⟨hal-01431971⟩
  • François Bertucci, Pascal Finetti, Nathalie Cervera, Emmanuelle Charafe-Jauffret, Emilie Mamessier, et al.. Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers. Cancer Research, American Association for Cancer Research, 2006, 66 (9), pp.4636-4644. ⟨10.1158/0008-5472.CAN-06-0031⟩. ⟨hal-03606415⟩
  • E Charafe-Jauffret, C Ginestier, F Monville, P Finetti, José Adelaïde, et al.. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene, Nature Publishing Group, 2006, 25 (15), pp.2273-2284. ⟨10.1038/sj.onc.1209254⟩. ⟨hal-01431970⟩
  • François Bertucci, Pascal Finetti, Nathalie Cervera, Dominique Maraninchi, Patrice Viens, et al.. Gene Expression Profiling and Clinical Outcome in Breast Cancer. OMICS, Mary Ann Liebert, 2006, 10 (4), pp.429-443. ⟨10.1089/omi.2006.10.429⟩. ⟨hal-03623836⟩
  • B Ballester, O Ramuz, C Gisselbrecht, G Doucet, L Loi, et al.. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene, Nature Publishing Group, 2006, 25 (10), pp.1560-1570. ⟨10.1038/sj.onc.1209178⟩. ⟨hal-01612147⟩
  • Elizabeth Devilard, Franck Bladou, Olivier Ramuz, Gilles Karsenty, Jean-Philippe Dalès, et al.. FGFR1 and WT1 are markers of human prostate cancer progression.. BMC Cancer, BioMed Central, 2006, 6, pp.272. ⟨10.1186/1471-2407-6-272⟩. ⟨inserm-00121110⟩
  • François Bertucci, Pascal Finetti, Nathalie Cervera, Emmanuelle Charafe-Jauffret, José Adélaïde, et al.. Comparison of Induced Sputum and Bronchoalveolar Lavage in Lung Transplant Recipients. The Journal of Heart and Lung Transplantation, Elsevier, 2006, 25 (5), pp.523-532. ⟨10.1016/j.healun.2005.12.009⟩. ⟨hal-03583497⟩
  • Anthony Gonçalves, Genevieve Monges, ying yang, Fabienne Palmerini, Patrice Dubreuil, et al.. Response of a KIT-Positive Extra-Abdominal Fibromatosis to Imatinib Mesylate and KIT Genetic Analysis. JNCI: Journal of the National Cancer Institute, Oxford University Press (OUP), 2006, 98 (8), pp.562-563. ⟨10.1093/jnci/djj137⟩. ⟨hal-03623835⟩
  • Sylviane Olschwang, Frédéric Viret, Geneviève Monges, Jean-François Seitz, Nicolas Sevenet, et al.. Identification des facteurs génétiques associés à l'évolution des cancers coliques. médecine/sciences, EDP Sciences, 2006, 22, pp.45-49. ⟨10.1051/medsci/2006221s45⟩. ⟨hal-03623837⟩
  • Véronique Gelsi-Boyer, Béatrice Orsetti, Nathalie Cervera, Pascal Finetti, Fabrice Sircoulomb, et al.. Comprehensive profiling of 8p11-12 amplification in breast cancer.. Molecular Cancer Research, American Association for Cancer Research, 2005, 3 (12), pp.655-67. ⟨10.1158/1541-7786.MCR-05-0128⟩. ⟨inserm-00158812⟩
  • François Bertucci, Pascal Finetti, Jacques Rougemont, Emmanuelle Charafe-Jauffret, Nathalie Cervera, et al.. Gene Expression Profiling Identifies Molecular Subtypes of Inflammatory Breast Cancer. Cancer Research, American Association for Cancer Research, 2005, 65 (6), pp.2170-2178. ⟨10.1158/0008-5472.can-04-4115⟩. ⟨hal-03623838⟩
  • Norbert Vey, Marie-Joëlle Mozziconacci, Agnès Groulet-Martinec, Stéphane Debono, Pascal Finetti, et al.. Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. Oncogene, Nature Publishing Group, 2004, 23 (58), pp.9381-9391. ⟨10.1038/sj.onc.1207910⟩. ⟨hal-03623840⟩
  • François Bertucci, Nathalie Borie, Christophe Ginestier, Agnès Groulet, Emmanuelle Charafe-Jauffret, et al.. Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene, Nature Publishing Group, 2004, 23 (14), pp.2564-2575. ⟨10.1038/sj.onc.1207361⟩. ⟨hal-03623842⟩
  • O Baris, F Savagner, V Nasser, Béatrice B. Loriod, S Granjeaud, et al.. Gene expression profiling of thyroid mitochondria rich tumours reveals a coordinated up-regulation of genes involved in oxidative metabolism. Biochimica biophysica acta (BBA) - Bioenergetics, Elsevier, 2004, 1657, pp.84-85. ⟨hal-01612149⟩
  • O Baris, F Savagner, V Nasser, Béatrice B. Loriod, S Granjeaud, et al.. Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. Journal of Clinical Endocrinology and Metabolism, Endocrine Society, 2004, 89 (2), pp.994-1005. ⟨10.1210/jc.2003-031238⟩. ⟨hal-01612150⟩
  • F Bertucci, P Finetti, J Rougemont, E Charafe-Jauffret, V Nasser, et al.. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Research, American Association for Cancer Research, 2004, 64 (23), pp.8558-8565. ⟨10.1158/0008-5472.CAN-04-2696⟩. ⟨hal-01612154⟩
  • Emmanuelle Charafe-Jauffret, Carole Tarpin, Valérie-Jeanne Bardou, François Bertucci, Christophe Ginestier, et al.. Immunophenotypic analysis of inflammatory breast cancers: identification of an‘inflammatory signature’. Journal of Pathology, Wiley, 2004, 202 (3), pp.265-273. ⟨10.1002/path.1515⟩. ⟨hal-03623843⟩
  • F Bertucci, S Salas, S Eysteries, V Nasser, P Finetti, et al.. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene, Nature Publishing Group, 2004, 23 (7), pp.1377-1391. ⟨10.1038/sj.onc.1207262⟩. ⟨hal-01612151⟩
  • C Thieblemont, V Nasser, P Felman, K Leroy, S Gazzo, et al.. Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood, American Society of Hematology, 2004, 103 (7), pp.2727-2737. ⟨10.1182/blood-2003-06-2160⟩. ⟨hal-01612152⟩
  • Fabrice Lopez, Jacques Rougemont, Béatrice Loriod, Aude Bourgeois, Laurence Loï, et al.. Feature extraction and signal processing for nylon DNA microarrays.. BMC Genomics, BioMed Central, 2004, 5 (1), pp.38. ⟨10.1186/1471-2164-5-38⟩. ⟨inserm-00112016⟩
  • Christophe Ginestier, Valérie-Jeanne Bardou, Cornel Popovici, Emmanuelle Charafe-Jauffret, François Bertucci, et al.. Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer. International Journal of Cancer, Wiley, 2003, 107 (5), pp.854-862. ⟨10.1002/ijc.11462⟩. ⟨hal-03623844⟩
  • François Bertucci, Patrice Viens, Pascal Hingamp, Valery Nasser, R�mi Houlgatte, et al.. Breast cancer revisited using DNA array-based gene expression profiling. International Journal of Cancer, Wiley, 2003, 103 (5), pp.565-571. ⟨10.1002/ijc.10867⟩. ⟨hal-03623846⟩
  • F Bertucci, Béatrice B. Loriod, V Nasser, S Granjeaud, R Tagett, et al.. Gene expression profiling of breast carcinomas using Nylon DNA arrays. Comptes Rendus Biologies, Elsevier, 2003, 326 (10-11), pp.1031-1039. ⟨10.1016/j.crvi.2003.09.010⟩. ⟨hal-01612156⟩
  • François Bertucci, Patrice Viens, Rebecca Tagett, Catherine Nguyen, Rémi Houlgatte, et al.. DNA Arrays in Clinical Oncology: Promises and Challenges. Laboratory Investigation, Nature Publishing Group, 2003, 83 (3), pp.305-316. ⟨10.1097/01.lab.0000059936.28369.19⟩. ⟨hal-03623845⟩
  • F Magrangeas, V Nasser, H Avet-Loiseau, Béatrice B. Loriod, O Decaux, et al.. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood, American Society of Hematology, 2003, 101 (12), pp.4998-5006. ⟨10.1182/blood-2002-11-3385⟩. ⟨hal-01612158⟩
  • Christophe Ginestier, Emmanuelle Charafe-Jauffret, François Bertucci, François Eisinger, Jeannine Geneix, et al.. Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers. American Journal of Pathology, American Society for Investigative Pathology, 2002, 161 (4), pp.1223-1233. ⟨10.1016/s0002-9440(10)64399-4⟩. ⟨hal-03623848⟩
  • François Bertucci, F. Eisinger, R. Tagett, H. Sobol, D. Birnbaum. Re: Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers. JNCI: Journal of the National Cancer Institute, Oxford University Press (OUP), 2002, 94 (19), pp.1506-1507. ⟨10.1093/jnci/94.19.1506⟩. ⟨hal-03623849⟩
  • F Bertucci, V Nasser, S Granjeaud, F Eisinger, José Adelaïde, et al.. Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Human Molecular Genetics, Oxford University Press (OUP), 2002, 11 (8), pp.863-872. ⟨10.1093/hmg/11.8.863⟩. ⟨hal-01612162⟩
  • D. Genre, P. Viens, F. Bertucci, C Chabannon, G. Gravis, et al.. Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens. Bone Marrow Transplantation, Nature Publishing Group, 2002, 29 (11), pp.881-886. ⟨10.1038/sj.bmt.1703556⟩. ⟨inserm-03199676⟩
  • François Bertucci, François Eisinger, Rémi Houlgatte, Patrice Viens, Daniel Birnbaum. Gene-expression profiling and identification of patients at high risk of breast cancer. The Lancet, Elsevier, 2002, 360 (9327), pp.173-174. ⟨10.1016/s0140-6736(02)09399-6⟩. ⟨hal-03623850⟩
  • C. Popovici, C. Basset, F. Bertucci, A. Orsetti, J. Adelaide, et al.. Reciprocal translocations in breast tumor cell lines: Cloning of a t(3;20) that targets the FHIT gene. Genes, Chromosomes and Cancer, Wiley, 2002, 35 (3), pp.204--218. ⟨10.1002/gcc.10107⟩. ⟨hal-02197538⟩
  • Elisabeth Devilard, François Bertucci, Pascal Trempat, Réda Bouabdallah, Béatrice B. Loriod, et al.. Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene, Nature Publishing Group, 2002, 21 (19), pp.3095-3102. ⟨10.1038/sj.onc.1205418⟩. ⟨hal-01612161⟩
  • F Bertucci, R Houlgatte, C Nguyen, A Benziane, V Nasser, et al.. Molecular typing of breast cancer: transcriptomics and DNA microarrays. Bulletin du Cancer, John Libbey Eurotext, 2001, 88 (3), pp.277-286. ⟨hal-01612164⟩
  • F Bertucci, Béatrice B. Loriod, R Houlgatte, C Nguyen. Gene expression profiling using nylon arrays of candidates genes. Journal of Neurochemistry, Wiley, 2001, 78, pp.110. ⟨hal-01612165⟩
  • F Bertucci, Béatrice B. Loriod, R Tagett, S Granjeaud, D Birnbaum, et al.. DNA arrays: technological aspects and applications. Bulletin du Cancer, John Libbey Eurotext, 2001, 88 (3), pp.243-252. ⟨hal-01612166⟩
  • F Bertucci, R Houlgatte, A Benziane, S Granjeaud, José Adelaïde, et al.. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Human Molecular Genetics, Oxford University Press (OUP), 2000, 9 (20), pp.2981-2991. ⟨10.1093/hmg/9.20.2981⟩. ⟨hal-01612167⟩
  • F Bertucci, S van Hulst, K Bernard, Béatrice B. Loriod, S Granjeaud, et al.. Expression scanning of an array of growth control genes in human tumor cell lines. Oncogene, Nature Publishing Group, 1999, 18 (26), pp.3905-3912. ⟨10.1038/sj.onc.1202731⟩. ⟨hal-01612170⟩
  • F Bertucci, K Bernard, Béatrice B. Loriod, yi-Chung Chang, S Granjeaud, et al.. Sensitivity issues in DNA array-based expression measurements and performance of nylon microarrays for small samples. Human Molecular Genetics, Oxford University Press (OUP), 1999, 8 (9), pp.1715-1722. ⟨10.1093/hmg/8.9.1715⟩. ⟨hal-01612169⟩

Book sections2 documents

  • Maxime Garcia, Pascal Finetti, François Bertucci, Daniel Birnbaum, Ghislain Bidaut. Detection of Driver Protein Complexes in Breast Cancer Metastasis by Large-Scale Transcriptome–Interactome Integration. Gene Function Analysis, 1101, Humana Press, pp.67-85, 2014, Methods in Molecular Biology, ⟨10.1007/978-1-62703-721-1_5⟩. ⟨hal-03623759⟩
  • F Bertucci, R Houlgatte, S Granjeaud, V Nasser, Béatrice B. Loriod, et al.. Prognosis of breast cancer and gene expression profiling using DNA arrays. Microarrays, Immune Responses and Vaccines, 975, pp.217-231, 2002, 0077-8923;1-57331-446-3. ⟨10.1111/j.1749-6632.2002.tb05954.x⟩. ⟨hal-01612160⟩

Preprints, Working Papers, ...4 documents

  • Anaïs Aulas, Maria Lucia Liberatoscioli, Pascal Finetti, Olivier Cabaud, David Birnbaum, et al.. Epithelial-to-mesenchymal transition lowers the cholesterol pathway, which influences colon tumors differentiation. 2022. ⟨hal-03623627⟩
  • Jessica Roelands, Wouter Hendrickx, Raghvendra Mall, Mohamad Saad, Kyle Halliwill, et al.. Conditional activation of immune-related signatures and prognostic significance: a pan-cancer analysis. 2022. ⟨hal-03623694⟩
  • yuchen Guo, Monica Gabola, Rossano Lattanzio, Conception Paul, Valérie Pinet, et al.. Loss of cyclin A2 in murine colonic epithelial cells disrupts colon homeostasis by triggering DNA damage and dysplasia and high cyclin A2 expression is a good-prognosis factor in patients with colorectal cancer. 2022. ⟨hal-03623690⟩
  • Avais Daulat, Mônica Wagner, Stéphane Audebert, Malgorzata Kowalczewska, Jeremy Ariey-Bonnet, et al.. The serine/threonine kinase MINK1 directly regulates the function of promigratory proteins. 2022. ⟨hal-03623628⟩